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Extracellular signals specify cell fate and behavior by activating intracellular 
signaling networks and transcriptional programs under both physiological and 
pathological conditions. The signal transducer and activator of transcription 
(STAT) proteins are important molecules transmitting extracellular signals 
such as cytokines, growth factors and hormones, and thus critically regulate a 
plethora of biological processes. This thesis explores the context-dependent 
roles of two STAT proteins (STAT3 and STAT5) in two kinds of diseases, 
cancer and autoimmunity.  
First, we found that tumor cell-derived soluble factors strongly activated 
STAT3 in mouse primary endothelial cells, suggesting a potential role of 
endothelial-specific STAT3 in responding to tumor development. By using a 
knockout mouse strain in which STAT3 was specifically deleted in endothelial 
cells (ECs), we demonstrated that loss of STAT3 in ECs suppressed tumor 
development. Second, we performed mechanistic study and revealed the 
importance of EC-specific STAT3 in mediating tumor angiogenesis. Loss of 
STAT3 in ECs remarkably reduced blood vessel density in tumor masses. 
Furthermore, wild-type ECs exhibited enhanced ability to form tubes in 
response to stimulation by tumor cell-derived soluble factors, whereas this 
kind of ability was severely impaired by STAT3 deletion. EC migration was 
also disabled by STAT3 deletion. Given STAT3 functions as transcription 
factor, microarray analysis indicated multiple vascularization relevant genes 




reduction of regulatory T (Treg) cells, key suppressors of anti-tumor immunity, 
in tumor masses with STAT3 deletion in ECs. In vitro assay showed Treg 
adhesion to ECs was attenuated by EC-specific STAT3 deletion, suggesting 
that STAT3 activity in ECs may regulate Treg-EC interaction and Treg 
transmigration in tumor masses. Collectively, our study reveals the importance 
of EC-specific STAT3 in tumor development at least via modulating 
angiogenesis and Treg recruitment.  
We explored T-cell-specific function of STAT5 in autoimmunity, since 
STAT3 in this aspect is well documented. T-cell-specific deletion of STAT5 
protected mice from experimental arthritis, mouse models of human 
rheumatoid arthritis. Mechanistic study revealed that loss of STAT5 resulted 
in defective arthritogenic potential of CD4+ T cells, which was independent of 
IL-17 or IFN-γ production but was largely due to impaired GM-CSF 
production. Intra-articular administration of exogenous GM-CSF can partially 
restore arthritis development in STAT5 conditional-knockout mice. 
Furthermore, with insufficient GM-CSF production, STAT5-deficient CD4+ T 
cells were attenuated in accumulating neutrophils and inducing effective 
synovitis. In addition, we showed GM-CSF was a potent stimulator of pro-
inflammatory cytokines (IL-6 and IL-1β) from monocytes/macrophages, 
dendritic cells and synovial fibroblasts. In summary, this study suggests a 
functional importance of STAT5-regulated GM-CSF-producing CD4+ T cells 
in arthritis pathology and may provide clues for therapeutic intervention in 
rheumatoid arthritis. 
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CHAPTER 1 INTRODUCTION 
1.1 Overview 
Extracellular signals specify cell fate and behavior by activating intracellular 
signaling networks and transcriptional programs under both physiological and 
pathological conditions. The signal transducer and activator of transcription 
(STAT) proteins are important molecules transmitting extracellular signals 
such as cytokines, growth factors and hormones, and inducing transcription of 
downstream genes, and thus critically regulate a plethora of biological 
processes. This thesis explores the context-dependent roles of two STAT 
proteins (STAT3 and STAT5) in two kinds of diseases, cancer and 
autoimmunity. Therefore, in this chapter, brief introduction on both projects 
will be reviewed. 
In the following sections, a detailed review on JAK-STAT pathway, tumor 
angiogenesis, antitumor immunity, tumor immune suppression, autoimmune 
disease, and effectors and mediators in rheumatoid arthritis will be presented. 
1.2 Mechanisms of STAT activation 
STAT proteins were discovered from the study of interferon (IFN). About 30 
years ago, researchers found that a quick and robust transcriptional increase of 
interferon-stimulated genes (ISGs) could be induced by IFN stimulation 
(Friedman et al., 1984; Larner et al., 1984). Later, ISGF3 complex was 
purified and separated as four obvious bands (Fu et al., 1990). The four 
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components of ISGF3 complex were subsequently cloned and named as 
STAT2, STAT1 p84/p91, and IRF9 (Fu, 1992; Shuai et al., 1992). Meanwhile, 
a mutant screening for IFN pathway required genes uncovered the first 
participated JAK family member, TYK2 (Velazquez et al., 1992). Another two 
JAK family members known at that time were JAK1 and JAK2. Shortly after 
that, researchers revealed that different JAK family members were required 
for STAT1 and STAT2 phosphorylation in IFN pathways (Muller et al., 1993). 
The concept of JAK-STAT pathway was thus recognized. Thereafter, the 
catalog of four JAK family members (TYK2, JAK1, JAK2, and JAK3) and 
seven STAT family members (STAT1, STAT2, STAT3, STAT4, STAT5A, 
STAT5B, and STAT6) were completed quickly (Stark and Darnell, 2012). 
Afterwards, tremendous studies were carried out to decipher the structure and 
understand the biological functions of JAK-STAT family members. 
 
 
Figure 1-1 Functional domains of JAK and STAT proteins 
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Janus Kinase family proteins share structure of four domains: C-terminal 
tyrosine kinase domain, pseudokinase domain, FERM domain, and Src 
homology (SH2) domain. (Figure 1) (Wilks et al., 1991). The pseudokinase 
domain is non-catalytic but an essential regulatory element for catalytic 
function of JAKs (Saharinen et al., 2000; Yeh et al., 2000). FERM domain is 
involved in receptor binding and essential regulatory functions (Hilkens et al., 
2001). SH2 domain recognizes phosphorylated-tyrosine residues. 
 
Figure 1-2 JAK-STAT pathway 
Ligand-receptor interaction activates pre-bound JAK kinase, which in turn 
tyrosine-phosphorylate receptor; STAT proteins bind to the phosphotyrosine 
on the receptor, get phosphorylated by JAKs, and detached from receptors and 
form dimers; STAT dimers then translocate to nucleus, bind to DNA and 
regulate transcription of downstream genes. 
 
JAK-STAT pathway is stimulated by ligand-receptor interaction (Figure 1-2). 
Upon stimulation, JAKs bind to and phosphorylate receptors on cell 
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membrane. The phosphorylated sites on receptors provide docking sites for 
STAT proteins via its SH2 domain (Greenlund et al., 1994). The receptor-
bound STAT proteins are then phosphorylated by JAKs. The SH2 domain also 
serves as a binding site for STAT dimerization through SH2-phosphotyrosine 
interactions after STATs detach from receptors (Schindler and Darnell, 1995). 
STAT homodimers or heterodimers then translocate to nucleus and bind to 
specific motif via DNA binding domain (DBD). The specific STAT-binding 
motif is named as interferon-gamma activated sequence (GAS). DNA-bound 
STAT proteins regulate transcription of target genes through its carboxyl 
terminal transcriptional activation domain (TAD) (O'Shea et al., 2002). 
Besides, the linker domain also plays a role in transcriptional activation (Yang 
et al., 1999).The amino terminal and coiled-coil domains are involved in 
protein-protein interaction (Vinkemeier et al., 1998; Zhang et al., 1999) 
(Figure 1-1).  
In summary, typical JAK-STAT pathway is described as: ligand-receptor 
interaction activates pre-bound JAK kinase, which in turn tyrosine-
phosphorylate receptor; STAT proteins bind to the phosphotyrosine on the 
receptor, get phosphorylated by JAKs, and detached from receptors and form 
dimers; STAT dimers then translocate to nucleus, bind to DNA and regulate 
transcription of downstream genes (Figure 1-2). 
Besides Janus kinase, STAT proteins can be activated by multiple mechanisms. 
Somatic mutation or overexpression of receptor tyrosine kinase including 
epidermal growth factor receptor (EGFR) (Garcia et al., 1997) and platelet 
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derived growth factor receptor (PDGFR) (Vignais et al., 1996) lead to 
activation of STAT proteins. Non-receptor kinase that can activate STATs 
includes Src and Abl(Ilaria and Van Etten, 1996). Cells transformed by the v-
src oncoprotein showed increased DNA-binding activity of STAT3 (Yu et al., 
1995). In addition, STAT activation can be induced by infections. For example, 
the effector protein cytotoxin-associated gene A (CagA) of Helicobacter 
pylori has been demonstrated to activate STAT3 in host epithelial cells 
(Bronte-Tinkew et al., 2009). The core protein of hepatitis C virus was shown 
to interact with and activate STAT3 (Yoshida et al., 2002). Taken together, 
STAT activation can be stimulated by various signals.  
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1.3 Tumor angiogenesis 
Growth of multicellular organisms requires formation of new blood vessels 
through vasculogenesis (endothelial-cell precursors differentiate and form 
neovessles) and angiogenesis (sprouting from pre-existing blood vessels) to 
supply nutrients and oxygen (Carmeliet and Jain, 2000). In the adult, 
formation of new capillaries only occurs through angiogenesis (Hanahan and 
Folkman, 1996). Angiogenesis is fundamental in the process of reproduction, 
development, and wound healing, under which angiogenesis is tightly 
regulated (Folkman and Shing, 1992). However, sustaining unregulated 
angiogenesis is observed in many disease, including arthritis, diabetes, and 
tumor (Folkman and Shing, 1992).  
As early as a century ago, researchers observed that tumor growth is usually 
accompanied by increased new capillaries (Ferrara and Kerbel, 2005). In 
1960s, Greenblatt and Shubi (Greenblatt and Shubi, 1968) and Ehrmann and 
Knoth (Ehrmann and Knoth, 1968) provided clear evidence that tumor cell-
secreted diffusible factors could promote tumor angiogenesis. Subsequently, in 
1971, Folkman proposed the hypothesis that tumor growth and metastasis 
require angiogenesis, which could be stimulated by tumor-derived substance, 
and therefore, targeting angiogenesis could be a promising anti-tumor strategy 
(Folkman, 1971). Since then, substantial research has been performed to 
search for factors that promote or against angiogenesis, some of which may be 
potential therapeutic targets to suppress development of tumor (Folkman et al., 
1971).  
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1.3.1 Formation of tumor vessels 
Folkman was the first to provide experimental evidence to demonstrated that 
tumors can only grow to limited size without assistance of newly formed 
blood vessels (Folkman, 1971). When small fragments of anaplastic 
carcinoma were implanted in an avascular site, the anterior chamber of a 
rabbit eye, tumors remain arrested in small size after initial limited growth 
(Gimbrone et al., 1972). Blood vessels supply nutrients and oxygen and 
dispose waste products to support tumor growth as well as provide the routines 
for tumor cells to metastasize to other organs (Ferrara and Kerbel, 2005). 
Initiation of tumor vasculature is termed as “angiogenic switch” (Hanahan and 
Folkman, 1996). Angiogenic switch is governed by the balance with pro-
angiogenic molecules (activators of endothelial cell proliferation and 
migration) on an arm and anti-angiogenic molecules (inhibitors) on the other 
arm (Hanahan and Folkman, 1996) (Figure 1-3). The angiogenic switch can be 
turned on when the balance is tilted to the arm of pro-angiogenic molecules 
(Carmeliet and Jain, 2000). Overexpression of pro-angiogenic factors can be 
induced by physiological stimuli (for example, hypoxia), oncogenes activation, 
and silencing of tumor suppressor genes (Bergers and Benjamin, 2003). 




Figure 1-3 The angiogenic balance.   
Angiogenic switch is governed by the balance of pro-angiogenic molecules 
(activators of endothelial cell proliferation and migration) and anti-angiogenic 
molecules (inhibitors). Representative pro- and anti- angiogenic factors are 
listed. When the balance is tilted to the arm of pro-angiogenic molecules, 
endothelial cells are switched from quiescent state to angiogenic state. 
(Bergers and Benjamin, 2003) 
Reproduced with permission from Nature Reviews Cancer. 
 
Carmeliet and Jain reviewed the modes of blood vessel formation in both 
normal tissues and tumor (Carmeliet and Jain, 2011b). In the embryonic 
development, bone marrow-derived endothelial precursors (angioblasts) 
differentiate to endothelial cells (ECs) that line vascular walls (a process 
termed as vasculogenesis). Normal tissues utilize sprouting angiogenesis to 
form new capillaries from pre-existing vessels. Blood vessels can also split to 
daughter vessels through a process named intussusception. These three modes 
could be hijacked by tumor cells. Moreover, tumor cells could also induce 
generation of new blood vessels by co-opting pre-existing vessels, vascular 
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mimicry (tumor cells mimic ECs to line tumor vessels), and direct transition of 
tumor stem cells to endothelial cells (Bergers and Benjamin, 2003).  
1.3.2 Abnormal tumor blood vessels 
Tumor blood vessels are morphologically and functionally abnormal. Tumor 
vasculatures show chaotic network of tortuous vessels with extensive 
branching and increased variability of diameter comparable to normal 
vasculatures under scanning electron microscopy (Konerding et al., 1999). The 
abnormality in tumor blood vessels may be induced by environmental stress 
and imbalance of angiogenic factors. For example, many tumors release high 
level of VEGF-A (vascular endothelial growth factor-A), which promote 
extensive sprouting and branching of tumor blood vessels and fluid leakage, 
leading to loss of function as barrier (Nagy et al., 2007). In addition, 
overlaying tumor cells compress intratumor blood vessels (Padera et al., 2004), 
leading to disordered and variable blood stream (De Val and Black, 2009).  
In contrast to uniform and continuous EC monolayer in normal tissues, tumor-
associated ECs form defective endothelial monolayer with numerous openings 
or interendothelial gaps, loose intercellular junctions, and discontinuous 
basement membrane (Carmeliet and Jain, 2000). Moreover, tumor-associated 
ECs are of abnormal shape and size. The small interendothelial gaps allow red 
blood cells to extravagate from the vessels and therefore form “blood lakes” 
for surrounding tumor cells (Dudley, 2012). Tumor cells can fill the small 
gaps and directly contact with flowing blood (Chang et al., 2000). Large 
opening about 1.5 μm are also observed on the tumor vessels (McDonald and 
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Choyke, 2003). The small interendothelilal gaps and large gaps contribute to 
the leakiness of tumor endothelium (Hashizume et al., 2000). 
1.3.3 Molecular mechanisms of angiogenesis 
The understanding of the regulation of cellular activities at molecular level is a 
prerequisite for revealing the mechanism underlying tumor angiogenesis as 
well as for drug development. To date, extensive studies have been undertaken 
on this topic.  
VEGF family proteins are prominent angiogenic factors (Ferrara, 2002). 
VEGF-A is the mostly studied VEGF family member, which promotes 
angiogenesis in both normal tissues and tumors (Ferrara, 2009; Nagy et al., 
2007). VEGF-A is indispensable for both vasculogenesis as well as 
angiogenesis during the process of embryonic development (Jakeman et al., 
1993). Genetically modified mice with deletion of VEGF-A are embryonic 
lethal because of the defects in vesculogenesis (Carmeliet et al., 1996).  
VEGF-A is frequently over-expressed in human cancers (Ferrara et al., 2003). 
Upregulation of VEGF-A can be induced via various signals, such as 
environmental factors (for example, hypoxia), cytokines (for example, IL-6), 
growth factors and hormones, chemokines, activation of oncogenes (for 
example, src), and loss of function of tumor suppressor genes (for example, 
p53) (Kerbel, 2008).  
VEGF-A binds to several receptors on cell surface, including VEGF receptor-
1 (VEGFR-1), VEGFR-2 and neuropilin receptors (NRP-1 and NRP-2) 
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(Ferrara et al., 2003). The pro-angiogenic effect of VEGF mainly signals 
through VEGFR-2 (Cross et al., 2003). VEGF binds to and induces the 
dimerization of VEGFR-2 on the surface of ECs, leading to activation of 
different pathways that promotes proliferation, migration and survival of ECs 
(Shibuya and Claesson-Welsh, 2006). NRP-1 and NRP-2 can signal 
independently as well as serve as co-receptors for VEGFR-2 to enhance its 
activity in angiogenesis (Neufeld and Kessler, 2008). How VEGFR-1 
contributes to sprouting angiogenesis remains elusive. Tumor cells are 
originally thought to have no VEGF receptors on their cell surface and 
therefore unable to response to VEGF (Kerbel, 2008). However, tumor cells of 
varied human cancers express VEGFR-1, indicating an autocrine mechanism 
of VEGF (Dallas et al., 2007; Kessler et al., 2007). The intracellular form of 
VEGFR-1 has also been reported to promote cell survival and growth through 
its response to intracrine VEGF in breast carcinoma cells (Lee et al., 2007). 
Platelet-derived growth factor (PDGF) family proteins contribute to the 
maturation of newly formed blood vessel (Jain, 2003). Angiogenic ECs 
produce PDGF-B to attract pericytes that express PDGF β receptor (PDGFR-β) 
to stabilize endothelial cell-lining walls (Gaengel et al., 2009; Hellberg et al., 
2010). PDGF-B knockout mice present less pericytes in the tumor-associated 
vessels in transplanted tumors (Abramsson et al., 2003). PDGF-B can also 
promote the endothelial proliferation and tube formation of PDGFR-β+ ECs 
(Battegay et al., 1994). 
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PDGFs and their receptors are highly expressed in gliomas and gastric 
carcinomas (Hermanson et al., 1992; Hermanson et al., 1996; Nakamura et al., 
1997). In a study of gastric cancer, prevalence of PDGF-A is correlated with 
poor prognosis and shorter overall survival (Katano et al., 1998). Genetically 
modified mice with overexpressed PDGF-B in neural progenitors or astrocytes 
results in malignant gliomas in a mouse study (Dai et al., 2001). Blockade of 
PDGFR reduced tumor growth largely due to pericyte detachment, which 
resulted in blood vessel immaturity (Bergers et al., 2003). 
The angiopoietin-Tie signaling system regulates blood vessel quiescence and 
also contributes to tumor angiogenesis following angiogenic switch (Augustin 
et al., 2009). Tie1-deleted mice have defects in vasculature, indicating a 
essential role of Tie1 in supporting the integrity of endothelium in 
angiogenesis (Puri et al., 1995). Tie2-deficient mice have reduced vessel 
branching and sprouting and are embryonic lethal (Dumont et al., 1992). By 
supporting endothelial cell survival and vessel maturation, angiopoietin-1 
(Ang-1) favors tumor growth (Koblizek et al., 1998). Compare to wild type 
mice, genetically modified mice with over-expression of Ang1 form larger 
blood vessels with increased branching (Suri et al., 1998). However Ang-1 
also suppresses tumor extravasation by maintaining blood vessel integrity 
(Falcon et al., 2009).  
Moreover, tumor angiogenesis is also regulated by TGF-β, Notch, Wnt 
signaling pathway, as well as junction molecules and G protein coupled 
receptors (Carmeliet and Jain, 2011b). These studies advance our 
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understanding of tumor angiogenesis on molecular basis and offer promising 
therapeutic targets. Further exploration on unrevealed molecular regulation 
behind tumor angiogenesis is necessary and urgent. 
1.4 Antitumor immunity and tumor immune suppression 
Tumors grow within a stromal network, called tumor microenvironment, that 
supports the proliferation of neoplastic cells (Kerkar and Restifo, 2012). The 
tumor microenvironment contains multiple types of cells such as neovascular 
endothelium and infiltrating immune cells, and various soluble factors such as 
cytokines and chemokines. Almost all types of immune cells can infiltrate in 
human tumors, including lymphocytes, dendritic cells, macrophages, nature 
killer (NK) cells, and mast cells (Fridman et al., 2012) (Figure 1-4).  Tumor-
infiltrating immune cells have dual functions: suppressing tumor growth by 
eliminating neoplastic cells, or supporting tumor progression by suppressing 
antitumor immunity (Schreiber et al., 2011). Delineating the complex immune 
activities in tumors would provide important clues for development of 
effective tumor immunotherapies. 




Figure 1-4 Tumor microenvironment. 
Tumors are infiltrated with various immune cells, including T cell, B cells, 
DCs, macrophages, NK cells, and mast cells (Fridman et al., 2012).  
Reprinted with permission from Nature Review Cancer. 
 
1.4.1 Antitumor immunity 
Nearly fifty years ago, Burnet proposed the concept of cancer 
immunosurveillance that adaptive immune system protects hosts from tumor 
development (Burnet, 1957). The role of immune system as a tumor 
suppressor was reassessed by 1990s, when mouse genetic-modification 
technique became mature and well established. Compare to immunocompetent 
mice, immunodeficient mice grow much more tumor masses in the 
carcinogen-induced tumor models (Shankaran et al., 2001). Mice that lack 
immune effector molecules are more susceptible to spontaneous tumors 
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(Smyth et al., 2001). In human studies, tumor immunosurveillance is 
evidenced by paraneoplastic diseases, autoimmune neurological disorders 
resulted from a strong antitumor immune response to tumor burden (Darnell, 
1996). Increasingly studies provide clear evidence of antitumor immunity in 
early stage of tumor development (Girardi et al., 2001; Vesely et al., 2011). 
Immune system recognize tumor cells through tumor antigens. Nowadays, the 
molecular identification of tumor antigens has been well established, resulting 
in the characterization of several main types of tumor antigens (Brichard and 
Lejeune, 2007). The first type is “tumor-specific, shared antigens”, which are 
frequently expressed in certain tumors, including melanoma, sarcoma, and 
lung carcinoma (Brasseur et al., 1995; Weynants et al., 1994). Examples of 
shared tumor antigens are melanoma-associated antigen (MAGE) gene 
families, of which MAGE-A3 is now a therapeutic target of extensive clinical 
research (Brichard and Lejeune, 2007). The other types of tumor antigens are 
mutated genes encoded antigens (Boon and van der Bruggen, 1996), non-
mutated but overexpressed proteins by cancer cells (Robbins et al., 1995), 
differentiation antigens specific to cancer’s tissue of origin (Boon and van der 
Bruggen, 1996), and viral antigens (Stanley, 2007). 
Dendritic cells (DCs) are presented in the core of tumor masses (Fridman et al., 
2012). Cancer cells express chemokines such as chemokine (C-C motif) ligand 
20 (CCL20) to attract immature DCs (Palucka and Banchereau, 2012). As 
professional antigen-presenting cells (APCs), immature DCs capture tumor 
antigens for processing, then become active, and migrate to lymph nodes 
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where they prime T cells and B cells to stimulate an protective antigen-
specific antitumor immune response (Motz and Coukos, 2013). The processed 
tumor antigens are presented as peptide-major histocompatibility complex 
molecules (pMHC) complex to T cell receptor (TCR) complex, which initiates 
differentiation of naïve T cells into effector T cells that contribute to antitumor 
immunity (Darnell, 1996). 
DCs also activate NK cell and natural killer T (NKT) cell response, which 
rapidly kills tumor cells and also produces essential cytokines (Mellman and 
Steinman, 2001). Accumulating evidence shows that NK cells contribute to 
control of blood tumors and solid tumors (Liu et al., 2012; Mishra et al., 2010). 
In patients with gastrointestinal stromal tumors (GIST), NK cells can be 
activated by Imatinib mesylate therapy, which is correlated with progress-free 
survival. Alternative spliced isoforms of NK cell receptor NKp30 predict the 
clinical outcomes of patients. NKp30a and NKp30b isoforms exert 
immunostimulatory characteristics, whereas NKp30c isoform transmit 
immunosuppressive signals (Delahaye et al., 2011). NKT cells have either 
antitumor or immunoregulatory activities in an immunologic context-
dependent manner (Gajewski et al., 2013). 
T cells-infiltrated tumor phenotype correlates with good clinical outcome in 
many human cancers, including meker cell carcinoma, urothelial cells 
carcinoma, melanoma, breast, ovarian, colorectal, esophageal, and head and 
neck cancers (Fridman et al., 2012). Tumors with strong T cell infiltration 
express high levels of T-cell-recruiting chemokines (Harlin et al., 2009). After 
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the priming by DCs, T cells move out from lymph nodes and cross the neo-
vessels to reach tumor sites.  
Tertiary lymphoid structures (TLS) have been discovered in tumor 
microenvironment, which also help to explain T cell infiltration in tumors (de 
Chaisemartin et al., 2011). TLSs exhibit are similar structure of secondary 
lymphoid structures and present in many tumors (Martinet et al., 2012). 
Tumors express chemokines such as CCL21 to recruit both naïve T cells and 
activated DCs, implying that antigen presenting may occur within TLS in 
tumor microenvironment (Harlin et al., 2009; Messina et al., 2012). TLS in 
tumors is also associated with a favorable outcome in patients with lung 
cancer (de Chaisemartin et al., 2011) and colorectal cancer patients (Di Caro et 
al., 2014). 
Though the exact T cell types that essential for antitumor immunity are not 
completely clear, CD8+ effector T cells are unquestionable key contributors. In 
a clinical study of colorectal cancer, the high frequency of tumor-infiltrating 
CD8+ T cells is associated with good outcome and prolonged survival (Pages 
et al., 2005). Strong infiltration of CD8+ T cells into tumors is predictive of 
increased overall survival of patients with various tumors, including metastatic 
colon cancer (Halama et al., 2011), hepatocellular carcinoma (Gao et al., 
2007), and leukemia (Gonzalez-Rodriguez et al., 2010). Upon priming by DCs, 
naïve CD8+ T cells initiate differentiation to effector CD8+ T cells, named as 
cytotoxic T lymphocytes (CTLs). Tumor microenvironment express 
chemokine (C-X-C motif) ligand 9 (CXCL9) and CXCL10 to attract CTLs 
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through CXC chemokine receptor 3 (CXCR3) (Dengel et al., 2010; Kunz et al., 
1999).  
By recognizing specific antigens on tumor cells, CTLs kill tumor cells through 
multiple mechanisms. The tumor necrosis factor (TNF) superfamily members 
expressed by CTLs can initiate apoptosis of tumor cells through binding to 
corresponding surface receptors (Nagata and Golstein, 1995). CTLs also 
express perforin, which inserts itself into the cellular membrane of target cells 
to form holes, allowing granzymes to pass through. Once granzymes are 
delivered, tumor cells would be killed within 20 minutes (Cullen and Martin, 
2008; Rothstein et al., 1978; Shresta et al., 1998). The secreted cytokines, 
IFN-γ and TNF-α, of CTLs show pleiotropic antitumor activities. IFN-γ exerts 
angiostatic effect to mediate tumor rejection (Arenberg et al., 1996; Qin et al., 
2003). It can also stimulate the activation of macrophage (Schreiber et al., 
1986) and increase levels of tumor antigens (Wallach et al., 1982). TNF-α can 
induce apoptotic cell death of tumor cells (van Horssen et al., 2006). 
T helper (Th) subsets are also been found in tumor microenvironment. 
Substantial studies have been performed to investigate the correlation between 
tumor-infiltrating Th subsets and prognosis of cancer patients. However, the 
effects of different Th subsets in the context of tumor microenvironment are 
still controversial. Th1 cells are characterized by transcription factor T-bet and 
cytokine IFN-γ. Generally, abundant tumor-infiltrating Th1 cells and high 
secretion of IFN-γ are correlated with prolonged survival and favorable 
outcome in cancer patients (Knutson and Disis, 2005). Th2 cells are polarized 
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with exposure of interleukin 4 (IL-4). Th2 differentiation is controlled by 
transcription factor GATA-3. In a study of immunotherapy on melanoma 
patients, Th2-type responses are associated with active disease (Schultz et al., 
2004). Another report showed no significant correlation between Th2 
cytokines (IL-4, IL-5, and IL-13) in tumor microenvironment and disease 
prognosis for colorectal cancer patients (Tosolini et al., 2011). In a clinical 
study of pancreatic cancer patients, researchers proposed the ratio between 
tumor-infiltrating Th2 (GATA-3-positive) cells and Th1 (T-bet-positive) cells 
as a prognostic marker of patient survival, and suggested that Th2-type 
inflammation in pancreatic tumors was correlated to reduced patient survival 
(De Monte et al., 2011).  
IL-17-producing Th subset is named as Th17 cells, which is another well-
recognized Th subset (Harrington et al., 2005; Park et al., 2005). Transcription 
factor RORγt governs Th17 cells differentiation (Ivanov et al., 2006). 
Accumulating studies on effects of Th17 cells in tumor immunology lead to 
contradictory conclusions. Th17 cells were associated with favorabel outcome 
in patients with ovarian cancer (Kryczek et al., 2009), gastric cancer (Chen et 
al., 2011), and esophageal cancer (Lv et al., 2011), but with poor prognosis in 
cancer patients with lung carcinoma (Chen et al., 2010), hepatocellular 
carcinoma (Zhang et al., 2009), and colorectal cancer (Liu et al., 2011). In 
addition, Th17 cells have no prognostic significance in head and neck cancer 
patients (Zhang et al., 2010). 
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In summary, many players for immune systems are involved in eliminating 
tumor cells via multiple steps. Tumor-specific antigens are recognized by 
antigen-presenting cells, for example DCs. DCs migrate to lymph nodes and 
present processed antigens to T cells, which differentiate to effector T cells 
and transmigrate tumor vasculatures to reach tumor sites, where they 
recognize tumor antigens and eliminate tumor cells via various mechanisms. 
However, tumors utilize multiple strategies to suppress anti-tumor immunity 
by disrupting almost each step described above. Details will be discussed in 
the following sectors. 
1.4.2 Tumor immune suppression 
Tumors develop various mechanisms to interrupt different stages of anti-tumor 
responses, including interfering DC maturation and function, recruiting 
immunosuppressive cells, and suppressing T cell trafficking to tumor site. 
1.4.2.1 Immature or functionally impaired DCs 
DCs are crucial mediators that link innate and adaptive immunity. Maturation 
and activation of DCs are required for effectiveness of antitumor response, as 
reviewed in section 3.1. However, immature DCs and/or functionally impaired 
DCs are frequently found in most tumors (Palucka and Banchereau, 2012). 
Immature DCs express intermediate-level of MHC molecules and low-level of 
co-stimulatory molecules. Immature DCs present self-antigens and induce 
immune tolerance or unresponsiveness, in contrast to mature DCs that initiate 
activation and differentiation of T cells, (Heath and Carbone, 2001). In general, 
they achieve immune tolerance by inducing T cell anergy, deleting self-
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reactive T cells or expanding regulatory and suppressor T cells (Steinman et 
al., 2003). 
Tumors can interrupt antigen-presenting process by switching monocyte 
differentiation (Chomarat et al., 2000). Monocytes can differentiate to either 
DCs or macrophages, which is tightly controlled by environmental cytokines. 
For example, tumor and its environment can release IL-6, which up-regulate 
macrophage colony-stimulating factor (M-CSF) receptor expressed by 
monocytes, allowing monocytes to consume autocrine M-CSF, and this 
process induces generation of macrophages (Chomarat et al., 2000).  
Growing evidence suggests that many tumor-secreted soluble factors can 
interfere maturation and function of DCs. For instance, VEGF, a well-
recognized pro-angiogenic factor secreted by cancer cells, can disrupt the 
maturation of DCs from precursors (Gabrilovich et al., 1996). Reduced DC 
infiltration was closely associated with VEGF production in gastric carcinoma 
tissue (Takahashi et al., 2004). A significant inverse correlation was also 
established between peripheral blood DC numbers and serum VEGF levels in 
colorectal cancer patient. Furthermore, DCs isolated from these patients 
showed reduced T-cell stimulation capability (Della Porta et al., 2005). 
Similar observations have also been reported in breast cancer, lung cancer, and 
head and neck cancer patients (Almand et al., 2000). Conversely, cancer 
patients treated with anti-VEGF antibody bevacizumab showed reduced 
number of immature DCs and correspondent increased mature DCs in 
peripheral blood (Osada et al., 2008).  
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The secretion of IL-10 by tumor microenvironment can inhibit fully 
maturation of DCs and therefore causes anergy in CD4+ T effector cells 
(Steinbrink et al., 1997). Upon exposure to certain tumor-derived factors, DCs 
skewed naïve CD4+ T cell differentiation towards IL-13-expressing Th2-like 
cells, which promoted tumor growth in humanized mice that were implanted 
with breast tumors (Aspord et al., 2007). 
High amounts of inhibitory and immune regulatory molecules are found on 
tumor associated DCs. A study on ovarian cancer patients showed that 
myeloid DCs (mDCs) from tumors express higher level of inhibitory molecule 
B7-H1, which can be upregulated by tumor-secreted factors, than those from 
healthy individuals (Curiel et al., 2003). Inhibition of B7-H1 enhances mDC-
regulated T-cell priming in a mouse study (Curiel et al., 2003). In addition to 
B7-H1, its receptor programmed death receptor-1 (PD-1) is increased on 
tumor-associated DCs. Although these B7-H1+PD-1+ DCs show conventional 
DC phenotype (CD11c+CD11b+), they are immature and associated with 
suppressed T cell activity and reduced tumor-infiltrating T cells (Krempski et 
al., 2011). 
The plasmacytoid DCs (pDCs), another major subset of DCs, also infiltrate 
some tumors (Cao et al., 2009). Human ovarian tumor cells express high 
amount of stromal-derived factor-1 (SDF-1) to recruit pDCs to tumors through 
CXCR4 (Zou et al., 2001). The presence of tumor-associated pDCs is strongly 
correlated with poor prognosis in breast cancer patients (Treilleux et al., 2004).  
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In ovarian cancer, pDCs can also promote tumor angiogenesis through 
production of proangiogenic factors (de Chaisemartin et al., 2011). 
1.4.2.2 Immunosuppressive cells 
Tumors microenvironment can recruit immunosuppressive cells including 
regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) to 
escape antitumor immunity. Many efforts have been made by researchers to 
study the functions of these populations and prognostic significance of their 
presence in tumors.  
In early 1970s, it is the first time that researchers described T cells with 
immunesupressive functions (Gershon and Kondo, 1970; Gershon and Kondo, 
1971). The essential role of CD4+CD25+ T cells in inhibiting antitumor 
responses was subsequently established in various mouse models (Berendt and 
North, 1980; Bursuker and North, 1984). Later studies revealed that 
development of Treg cells is controlled by transcription factor FoxP3 
(Fontenot et al., 2003; Hori et al., 2003), finally leading to Treg 
characterization by CD4+CD25+FoxP3+ markers (Wood and Sakaguchi, 2003). 
A strong infiltration of Treg cells has been described in different cancers, 
including gastric cancer (Sasada et al., 2003), pancreatic cancer (Hiraoka et al., 
2006), breast cancer (Liyanage et al., 2002), ovarian cancer (Woo et al., 2001), 
melanoma (Viguier et al., 2004), colorectal carcinoma (Somasundaram et al., 
2002), and hepatocellular carcinoma (Ormandy et al., 2005). High frequency 
of tumor-infiltrating Treg cells is associated with poor outcome in many 
cancers. For example, gastric carcinoma patients with increased CD4+CD25+ 
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T cells have a shorter survivor (Sasada et al., 2003). In pancreatic ductal 
adenocarcinomas patients, increased Treg cell infiltration correlated with 
progression of premalignant lesions to established tumors (Hiraoka et al., 
2006). Elevated amounts of Treg cells also predict an increased probability of 
late relapse and reduced survival of breast cancer patients (Bates et al., 2006). 
Interestingly, in a study of human ovarian carcinoma, Treg cells isolated from 
peripheral blood, ascites and tumors of patients showed identical capability of 
inhibiting antitumor immunity, indicating that quantitation of Treg cells 
matters for immunosuppression in tumor microenvironments (Curiel et al., 
2004). 
To suppress antitumor immune responses, multiple mechanisms can be 
enacted by Treg cells. The primary mechanism is the production of 
immunosuppressive factors by Treg cells. Evidence shows that Treg cells 
release IL-10 and transforming growth factor beta (TGF-β), which help to 
create an immune regulatory/suppressive environment (Vignali et al., 2008) 
and therefore contribute to tumor development (Loser et al., 2007; Strauss et 
al., 2007). It has been reported that Treg cells can secret proangiogenic factor 
VEGF, suggesting a role in promoting tumor angiogenesis (Facciabene et al., 
2011). CD25, also known as IL-2Rα, is receptor for IL-2, which sustain 
survival of T cells. Therefore, high expression of CD25 on Treg cells helps 
them to competitively consume IL-2. Insufficient IL-2 in tumor 
microenvironment leads to apoptosis of effector T cells (Pandiyan et al., 2007). 
Moreover, killing of effector T cells and DCs can be exerted by Treg cells 
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through TNF-related apoptosis-inducing ligand (TRAIL) pathway (Ren et al., 
2007) and granzyme-mediated cell death (Gondek et al., 2005).  
MDSCs are derived from myeloid cells and accumulated in various 
pathological conditions, such as cancer (Gabrilovich and Nagaraj, 2009). They 
are recognized as CD11b+Gr-1+ cell population in mouse (Bronte et al., 1998). 
MDSCs are a heterogeneous cell population that comprise of 
CD11b+Ly6ChiLy6Glo monocytic cells and CD11b+Ly6CloLy6Ghi granulocytic 
cells (Youn et al., 2008). Higher numbers of circulating MDSCs is correlated 
to a poor outcome in pancreatic adenocarcinoma patients (Porembka et al., 
2012). Highest percentage of MDSCs was observed in patients with serious 
metastatic tumors (Diaz-Montero et al., 2009). Besides, the prevalence of 
MDSCs was correlated with tumor burden and negatively associated with T 
cell numbers in the peripheral blood in a mammary tumor model (Donkor et 
al., 2009). Depletion of MDSCs by blocking antibodies promotes antitumor T-
cell responses and therefore suppresses tumor outgrowth (Sumida et al., 2012). 
MDSCs exert suppressive activities through multiple mechanisms. MDSCs 
present high expression of arginase 1 and inducible nitric oxide synthase 
(iNOS) leading to consumption of L-arginine and production of nitric oxide 
(NO), respectively (Bronte, 2009). The resultant scarcity of L-arginine would 
suppress expansion of T cells (Rodriguez et al., 2002). Nitric oxide (NO) can 
reduce the expression of MHC molecule (Harari and Liao, 2004), suppress 
JAK3/STAT5 signaling (Bingisser et al., 1998), and induce apoptosis of T 
cells (Rivoltini et al., 2002). MDSCs also release high amounts of reactive 
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oxygen species (ROS) to promote tumor development (Kusmartsev et al., 
2004). The secretion of ROS by MDSCs can be induced by various factors, 
including IL-6, IL-10, and TGF-β (Sauer et al., 2001). Blocking the 
production of ROS abrogated suppressive functions of MDSCs on CD8+ T 
cells activities (Kusmartsev et al., 2004). 
1.4.2.3 Suppressing T cell trafficking to tumor site 
Generation of effector T cells upon T-cell priming by functional DCs alone 
does not guarantee successful eradication of tumor cells. Activated T cells 
need to first circulate to tumor surrounding vasculature, and then adhere and 
extravasate tumor vasculature to interact with and finally effectively eliminate 
target tumor cells. Chemokines and their receptors have essential roles in T-
cell trafficking in tumor microenvironment. Tumor-secreted chemokines have 
been linked to effective immune cell infiltration and prolonged patient survival 
(Franciszkiewicz et al., 2012). Expression of different chemokines in tumor 
microenvironment may allow infiltration of selective immune cells. For 
example, human pancreatic tumor cells overexpress CCL20, also referred as 
macrophage inflammatory protein-3α (MIP-3α), to enhance infiltration of 
tumor-associated macrophages (TAMs) and to support tumor growth (Kleeff 
et al., 1999). Human basal and squamous cell skin cancer has been reported to 
evade immunosurveillance through reducing CCL7 expression. Blockade of 
CCL7 in a mouse model resulted in decreased leukocyte infiltration in skin 
tumors and enlarged primary tumor sizes (Pivarcsi et al., 2007). Moreover, 
cancer cells are able to posttranslationally modify chemokines, and this 
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modification can alter activities of chemokines (Loos et al., 2009).  An 
interesting study showed that reactive nitrogen species could induce 
nitrosylation of CCL2, making it selectively allow infiltration of myeloid cells 
and no longer attract CTLs to tumor sites. Administration of a novel drug, 
which inhibits modification of CLL2, enhanced intratumoral infiltration of 
CTLs in a mouse model (Molon et al., 2011). 
1.4.2.4 Role of endothelial cells in regulating immune suppression 
Accumulated evidence now indicates that tumor endothelium acts as an active 
barrier, which regulates adhesion and extravasation of immune cells (Boon et 
al., 2006; Lurquin et al., 2005). The tumor vasculature comprises abnormal, 
leaky, and fragile vessels that intensively sprout (Hanahan and Folkman, 
1996). Some reports have linked reduced extravasation and homing of T cells 
into tumors to alteration in tumor vasculature. Downregulated levels of cell 
adhesion molecules (CAMs) on tumor-associated endothelium have been 
described in several human cancers (Mauge et al., 2014). For instance, in 
samples of metastatic malignant melanoma tissues, researchers found no 
expression of adhesion molecules including selectins and intercellular 
adhesion molecule-1 (ICAM-1) on tumor vessels, even though high levels of 
these adhesion molecules was observed on endothelium of adjacent tissues. 
Correspondingly, this phenomenon was associated with insufficient CTLs 
infiltration into tumors but accumulated CTLs in the adjacent areas 
(Weishaupt et al., 2007). Mechanistically, it is generally believed that tumor 
microenvironment produces proangiogenic factors to suppress the expression 
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of CAMs on tumor vessels (Bouzin et al., 2007; Dirkx et al., 2003). Although 
TNF-α alone can upregulate CAMs expression and induce T cell adhesion on 
endothelial cells, it fails to induce sufficient upregulation of CAMs that 
required for T cell adhesion in the presence of VEGF (Bouzin et al., 2007) or 
basic fibroblast growth factor (bFGF) (Griffioen et al., 1996) in the tumor 
microenvironment,.  
Tumors can also augment expression of certain CAMs on tumor-associated 
vessels to selectively recruit immunosuppressive cell populations. It has been 
reported that the expression of common lymphatic endothelial and vascular 
endothelial receptor-1 (CLEVER-1; also named as stabilin-1) was increased 
on tumor endothelium of hepatocellular carcinoma samples. In vitro assays 
demonstrated that CLEVER-1 regulates migration of Treg cells across through 
endothelial cell monolayer (Shetty et al., 2011). Besides, tumor-associated 
endothelial cells express extrinsic mediators of apoptosis, such as TRAIL 
(Secchiero and Zauli, 2008) and Fas ligand (FasL) (Sata and Walsh, 1998), 
which can stimulate TNF-induced pathway and Fas-FasL-mediated pathway 
of apoptosis in effector T cells, respectively. 
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1.5 Autoimmunity and rheumatoid arthritis 
1.5.1 Immune self-tolerance and autoimmunity 
In section 1.4.1, I have reviewed how immune system recognizes and 
eliminates neoplastic cells to suppress the growth of tumors. However, in 
progressive and advanced tumors, immune resistance occurs because the 
activity of immune effector cells is suppressed under tumor microenvironment. 
Approaches that breakdown tumor immunosuppression are undergoing intense 
exploration to boost the immune attack against tumors, such as the clinical 
success of immune checkpoint blockade. As well known, the immune system 
primarily detects and defends against invading pathogens to protect hosts from 
infectious diseases. The process that immune system recognizes and erases 
foreign invaders, termed immune response, is strictly controlled. Under certain 
circumstance, the dysregulated immune system usually with unleashed 
immune responses attacks the body’s healthy cells and tissues, termed 
autoimmunity, resulting in the occurrence of severe inflammation and tissue 
damage.  
Physiologically, mammalian immune systems evolve several strategies to 
prevent immune responses against self-antigen, known as immune self-
tolerance. First, developing lymphocytes in the central generative organs that 
display self-reactive receptors are deleted by triggering cell death, one 
important mechanism of central tolerance (Palmer, 2003; Starr et al., 2003). 
Second, mature lymphocytes that have escaped from central tolerance are 
constrained in peripheral tissues through inducing anergy or triggering 
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activation-induced cell death, crucial mechanisms of peripheral tolerance 
(Alferink et al., 1999; Walker and Abbas, 2002). In addition, self-reactive 
lymphocytes may stimulate secondary V(D)J recombination to alter offending 
receptors, known as receptor editing (Nemazee and Hogquist, 2003).  These 
strategies are collectively implemented in a cell-intrinsic manner. Extrinsic 
controls also critically restrain the danger of self-reactive lymphocytes through 
limiting the availability of costimulatory signals, growth cytokines, and other 
factor that are required for effective immune responses. Specialized 
populations with immunosuppressive functions avoid clonal deletion and are 
crucial for maintaining self-tolerance and immune homeostasis. For instance, 
firm evidence supports Treg cells are a specialized immunosuppressive 
population, which potently suppresses the activity of self-reactive T cells 
through multiple mechanisms (Sakaguchi et al., 2008).   
The pathogenic mechanism of undesirable autoimmunity remains 
incompletely understood, but the self-reactive lymphocytes bear an immediate 
threat of autoimmunity.  The breakdown of immune self-tolerance leads to 
aberrant immune response towards self-antigen and resultant autoimmune 
diseases. Both environmental exposure and genetic factors have been reported 
to disrupt immune self-tolerance. The concordance of autoimmune diseases 
between genetically identical twins ranges often in 25~40%, which 
emphasizes the involvement of both environmental and genetic factors. 
Additionally, the occurrence of autoimmunity most commonly happens in late 
childhood to early adulthood, also suggesting the involvement of 
environmental exposure. Many environmental factors, such as infection, 
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vaccines and some chemicals, are considered as important triggers of 
autoimmunity (Molina and Shoenfeld, 2005; Powell et al., 1999). Technical 
advances in human genetics, in particular the wide application of genome-
wide association studies (GWAS), has identified numerous genetic risks 
involved in multiple types of autoimmune diseases (Gregersen and Olsson, 
2009). Genetic polymorphisms closely related to aberrant immune responses 
are frequently identified as shared pathways of autoimmunity by GWAS, for 
example MHC, TNF, IL12/23 pathway and PTPN22 (Cho and Feldman, 2015). 
Substantial evidence underpins the genetic basis of autoimmune diseases 
(Marson et al., 2015). Functional elucidation of disease-associated genetic 
risks are far from being understood and are undergoing exploration. There is 
also vast heterogeneity within one disease type, because of which further 
studies should incorporate genetic, developmental, environmental factors in a 
thorough manner.  
1.5.2 Rheumatoid arthritis as an autoimmune disease 
Rheumatoid arthritis (RA) is a human chronic inflammatory polyarthritis with 
unclear etiology, but the autoimmune process clearly contributes to the 
pathogenesis of RA. RA, with a prevalence up to 1% worldwide, usually 
affect small joints in hand and feet, but may also affect large movement joints 
as well as organs like eyes, skins and vasculature. RA is featured by synovial 
hyperplasia and autoantibody production. Progressive RA may cause pain, 
joint deformity, disability and systemic complication.  Up to date, there is no 
cure for RA, but there are several conventional and biologic medications, such 
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as NSAIDs, corticosteroids and TNF-α inhibitor, prescribed to control disease 
progression.   
Both genetic factors and environmental exposures in a complex interplay 
contribute to the pathogenesis of RA.  In twin studies with RA in Finland and 
UK, the concordance for monozygotic twins (12.3% and 15.4% respectively) 
is much higher than that for dizygotic twins (3.5% and 3.6% respectively), and 
the heritability of RA was estimated approximately 60%  (MacGregor et al., 
2000). The application of GWAS in RA field has revealed multiple genetic 
risk loci (Eyre et al., 2012; Okada et al., 2014). Among these identified risk 
loci, human leukocyte antigen (HLA) locus, especially HLA-DRB1, displays 
the strongest association with RA susceptibility (Raychaudhuri, 2010). 
Substantial studies lead to a hypothesis of shared epitope to understand the 
genetics of susceptibility to RA, in which the products of shared epitope HLA-
DRB1 may mediate the presentation of antigenic peptides to lymphocytes and 
confer susceptibility (Imboden, 2009). Outside the HLA region, a 
polymorphism in protein tyrosine phosphatase nonreceptor 22 (PTPN22) 
shows the strongest association with RA susceptibility (Gregersen, 2005). The 
polymorphism R620W in PTPN22 gene confers susceptibility in subgroups of 
RA that are positive for autoantibodies against cyclic citrullinated peptides 
(anti-CCP) (Plenge et al., 2005). PTPN22, also called Lyp, participates in 
negative regulation of the activity of TCR-proximal protein tyrosine kinase. 
The R620W substitution may result in an increased threshold of TCR 
signaling and thus the failure of clonal deletion of autoreactive T cells in 
thymus (Gregersen, 2005). Conversely, the same substitution may also result 
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in gain-of-function that inhibits suppressive function of Treg cells (Gregersen, 
2005). These genetic evidence together with functional studies in disease 
models highlight the significance of adaptive immunity in RA pathogenesis.  
As mentioned above, the heritability of RA was predicted approximately 60% 
in twins study, suggesting environmental exposure may account for a 
substantial proportion of RA risk.   Accompanied with an expanded list of 
genetic risk factors, more and more environmental exposures are also 
implicated in RA susceptibility. Among current known environmental 
exposures, smoking represents the most prominent risk factor in RA. 
Substantial studies have reproducibly proved that cigarette smoking is 
associated with RA susceptibility (Hoovestol and Mikuls, 2011). RA 
susceptibility increases with larger pack-years of cumulative smoking 
(Hoovestol and Mikuls, 2011). Interestingly, smoking exposure as a risk factor 
in RA appears to be reversible, namely that smoking abstinence for enough 
long time can mitigate the smoking-caused risk (Costenbader et al., 2006). 
Further studies suggest an association between smoking and HLA-DRB1 
shared epitope in RA susceptibility (Hoovestol and Mikuls, 2011). But the 
detailed mechanism connecting smoking to RA susceptibility is not fully 
elucidated yet. Other environmental exposures, including infectious agents and 
their products, silica dust and air pollutants. Although the mechanism behind 
the association between infection and RA susceptibility remains elusive, a 
longstanding postulation is that molecular mimicry during certain infection 
may breakdown immune tolerance and lead to autoimmunity.  Immune 
complex generated during infection may induce the production of 
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autoantibody against Fc fragment of immunoglobulin, which is implicated in 
RA pathogenesis. In addition, periodontal disease, caused by pathogenic 
bacteria such as Porphyromonas gingivalis, appears to correlate with RA 
susceptibility and disease severity (Dissick et al., 2010). Supportive evidence 
has implicated that the PAD expressed by P. gingivalis can catalyze the 
citrullination of host proteins (Wegner et al., 2010), which may induce the 
generation of autoantibodies against CCP (Klareskog et al., 2008).  The 
observation of three times higher incidence of RA in female than male 
suggests a potential role of sex hormones in RA pathogenesis (Ballow et al., 
1979; Cutolo, 2007).  
The first evidence that autoimmunity is essential for RA was the serological 
identification of rheumatoid factors in RA patients. Rheumatoid factors are 
autoantibodies with high affinity to Fc portion of immunoglobulin (Franklin et 
al., 1957), which are discovered in most of RA patients. In a model, 
rheumatoid factors induce the formation of immune complexes, which can 
recruit immune cells to joints contributing to local inflammation and 
destruction (Weigle, 1973).  Abundant T cell infiltration in rheumatoid joints 
and the strongest association of HLA (present antigens to CD4 T cells) with 
RA risk suggest that T cell activity participate RA pathogenesis. Antibodies to 
citrullinated proteins (ACPA) are present in about 60% of RA patients, and 
considered as specific serological marker of RA. This evidence together with 
function studies with animal models support the notion that RA is an 
autoimmune disease. The key effectors and mediators that contribute to RA 
pathogenesis are reviewed subsequently.  
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1.6 Effectors and mediators in RA pathogenesis 
The complex interplay between genetic factors and environmental exposures 
described above (1.5.2) promotes the loss of immune tolerance to self-antigens, 
for example CCP. The subsequent immune responses involved both adaptive 
and innate immune compartments might happen in peripheral lymphoid 
organs and then localize to target joints, where various immune cells and 
inflammatory mediators cause synovitis and hyperplasia in positive feedback 
manner. In the effector phase of RA, synovial hyperplasia as a major 
contributor together with other factors lead to cartilage damage and bone 
destruction.  Thus, I review the involvement and functions of key effector cells 
and cytokine mediators that contribute to synovitis (Figure 1-5).  
1.6.1 Adaptive and innate immune cells in synovitis  
The genetic basis of RA and presence of serological autoantibodies in RA 
patients clearly demonstrate the central role of adaptive immunity in early 
development of RA, which includes synovitis. T cells and B cells as dominant 
adaptive immune cells have received a lot of attention in RA study.  




Figure 1-5 Key effector cells and cytokine mediators in RA development. 
Both innate and adaptive immune cells, including T/B cells, DCs, Neutrophils, 
macrophages, and mast cells, contribute to synovitis. The interactions between 
immune cells and synovial fibroblasts, osteoclasts form positive feedback to 
drive the pathogenesis of RA. 
Reproduced with permission from (McInnes and Schett, 2011), Copyright 
Massachusetts Medical Society. 
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1.6.1.1 T cells 
Multiple genetic polymorphisms with strong association with RA 
susceptibility, such as HLA-DRB1 and PTPN22, link RA susceptibility to T 
cell response, in which products of these gene variants might affect the 
selection of immature T cell clone with self-reactive receptors, the 
presentation of self-antigen to mature T cells, the threshold of TCR signaling 
during T cell selection or activation, Treg suppressive effect and so on 
(Imboden, 2009). Autoreactive T cell responses against citrullinated peptides 
have been identified in RA (Ireland et al., 2006; Law et al., 2012). Abundant T 
cells infiltrate in inflamed synovium (Imboden, 2009). But how T cells 
functionally mediate synovitis remains insufficient understood. Various anti-T 
cell therapies have been tried in RA patients, but none of them is successfully 
put into clinical practice so far, due to limited efficacy or side-effect (Panayi, 
2006). Instead, the disruption of the interaction between APCs and T cells 
could be a promising therapeutic approach, as illustrated by success of 
Abatacept (CTLA4-Ig fusion protein) in treating moderate to severe RA. Of 
note, the broad deletion of T cells could delete both autoreactive and 
immunosuppressive T cells subsets, and the specific targeting of certain T cell 
subsets might be an approach worthy exploration, considering the much better 
understanding of T cell subset specification and their respective functions in 
recent years. Th1 is a predominant population of T cells in synonium of RA 
patients and is long considered as major effector (Berner et al., 2000).  
However, past decade has witnessed the explosive knowledge on Th17, which 
is proved to have a crucial role in various animal models of RA (Imboden, 
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2009). Th17 cells produce proinflammatory cytokines IL-17, IL-17F, IL-
21and TNF-α that can promote the mobilization and activation of 
macrophages and neutrophils, help B cell production of antibodies, induce 
fibroblast proliferation and so on. Nevertheless, human RA patients have 
limited percentage of Th17 cells in peripheral blood as well as synovial 
compartment (Yamada et al., 2008). The immunosuppressive function of Treg 
cells in RA appears to be disturbed (Behrens et al., 2007). In animal arthritis 
model, the deletion of Treg exacerbates disease (Morgan et al., 2003). 
Conversely, adoptive transfer of Treg can ameliorate the ongoing disease 
(Frey et al., 2005; Kong et al., 2012). To summarize, multiple lines of 
evidence, including immunogenetics of RA, T cell accumulation in inflamed 
synovium and findings from animal disease models, support a critical role of T 
cells in RA pathogenesis, but a detailed mechanism of T cell responses in RA 
pathogenesis remains to further delineated.  
1.6.1.2 B cells 
B cells-mediated humoral adaptive immunity is implicated in RA pathogenesis, 
but how the complex interplay between genetic factors and environmental 
exposures results in autoreactive B cells remains unclear. B cells are the 
cellular source of rheumatoid factors and ACPA, the serologic signature of RA. 
Rheumatoid factors are autoantibodies that can bind to Fc portion of 
immunoglobulin (Franklin et al., 1957), which may cause the formation of 
immune complexes and the subsequent recruitment of immune effector cells to 
joints (Weigle, 1973). ACPAs are highly specific to RA and are found in 
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about 60% of RA patients. In addition, ACPAs may predict a more aggressive 
disease course in comparison to ACPAs-negative patients. It is realized that 
ACPA occurrence is closely related to HLA risk loci, and in particular that 
HLA-DRB1 (shared epitope) loci is restrictedly seen in ACPA-positive 
population of RA (Klareskog et al., 2006; van der Helm-van Mil et al., 2007). 
Recently, it was reported that RA patient synovium-derived B cells produced 
autoantibodies with strong bias against CCP, but autoantibodies lost the 
reactivity to CCP when somatic mutations were reverted (Amara et al., 2013). 
This observation supports the pathogenic potential of ACPAs as well as 
autoreactive B cells in RA. Evidence from animal disease models also 
supports this notion. For instance, in a mouse study, B cell depletion delays 
experimental arthritis development (Loser et al., 2007). For another instance, 
transferring citrullinated fibrinogen-specific antibodies exacerbates disease in 
experimental autoimmune arthritis (Kuhn et al., 2006). Importantly, 
monoclonal antibodies against B cell surface marker CD20, is clinically 
applied in RA treatment (Edwards et al., 2004).   
1.6.1.3 Monocytes/Macrophages 
A variety of innate immune cells infiltrate synovial membrane and contribute 
to synovitis of RA, among which monocytes/macrophages are crucial effectors. 
Monocytes/macrophages are activated in RA (Liote et al., 1996). It was 
previously suggested that the synovial infiltration of monocytes/macrophages 
is positively correlated with RA disease activity (Tak et al., 1997). In a 
specific report, CD14+ monocytes mature into CD14+CD16+ cells which 
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infiltrate joint and may contribute to joint inflammation (Kawanaka et al., 
2002). Functional studies with animal disease models show that the depletion 
of monocytes/macrophages attenuates synovitis and joint destruction (Bruhl et 
al., 2007; Richards et al., 1999). Monocytes/macrophages participate in 
synovitis in multiple ways by phagocytic activity, antigen presentation activity 
and producing proinflammatory cytokines, matrix metalloproteinase (MMPs) 
nitric oxide, reactive oxygen species (ROS),  and so on (Kinne et al., 2000). In 
addition, monocytes/macrophages interact with T cells through contact-
dependent manner or soluble factors and actively participate in T cell 
differentiation and activation (Brennan et al., 2006). For example, CD14+ 
monocytes derived from synovial tissues of RA patients enhance Th17 
responses (Evans et al., 2009).  
1.6.1.4 Neutrophils 
Neutrophils are present abundantly in inflamed joints, including synovial 
membrane and synovial fluids, of RA patients. Neutrophils have great 
cytotoxic potential and contribute to the RA initiation and progression in 
multiple ways (Wright et al., 2014). It is now believed that RA disease activity 
and joint destruction directly correlates with neutrophil influx to joints. 
Immune complexes, such as rheumatoid factor-mediated formation of immune 
complexes, activate neutrophils. Under inflammation of RA, activated 
neutrophils delay apoptosis and prolong survival, and thus produce plenty of 
cytotoxic products, including various granule enzymes and ROS, which cause 
tissue damage (Pillinger and Abramson, 1995). In addition, neutrophils in 
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inflamed joints share some characteristics of monocyte/macrophages 
pertaining to producing proinflammatory cytokines and present antigens to T 
cells (Wright et al., 2010). Many RA therapeutic interventions, including 
NMARDs and biologic inhibitors, show a function of suppressing neutrophil 
activity (Wright et al., 2014). Functional studies with animal disease models 
support a critical role of neutrophils in mediating arthritis initiation and 
development (Tanaka et al., 2006; Wipke and Allen, 2001).  
1.6.2 Critical cytokines in RA pathogenesis 
Cytokines are crucial mediators in RA pathogenesis by regulating a broad 
spectrum of immune and inflammatory processes (McInnes and Schett, 2007). 
Many proinflammatory cytokines, including well-studied cytokines (TNF-α, 
IL-6 and IL-1β) and emerging cytokines (GM-CSF, IL-17, IL-21), exert 
multifunction in fostering immunity, inflammation and tissue damage.  
1.6.2.1 TNF-α 
TNF-α has a very broad spectrum of biological activities and plays a 
predominant role in rheumatoid synovitis. Monocytes/macrophages are major 
source of TNF-α, though T and B cells also produce TNF-α. As reviewed 
elsewhere (McInnes and Schett, 2007), TNF-α targets various cells, both 
immune cells and non-immune cells, and exerts multiple functions: it induces 
monocyte/macrophage activation and cytokine release; it regulates T cell 
activation and differentiation; it promotes neutrophil priming and oxidative 
burst; it activates synovial fibroblasts to secret proinflammatory cytokines and 
MMPs; it activates endothelial cells to upregulate the expression of adhesion 
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molecules and proinflammatory cytokines, etc. In most inflamed synovial 
membranes, TNF-α is readily detected. Prolonged TNF-α exposure in 
inflamed microenvironment dysregulates TCR signaling in T cells (Isomaki et 
al., 2001).  TNF-α inhibits the suppressive function of Treg cells, at least 
through one mechanism that TNF-α induces protein phosphatase 1 to 
dephosphorylate Foxp3, the transcription factor that control differentiation of 
Treg cells (Nie et al., 2013; Valencia et al., 2006). Treatment with anti-TNF-α 
stabilized Foxp3 and restores Treg function in RA patients (Nie et al., 2013; 
Valencia et al., 2006). TNF-α together with other proinflammatory cytokines, 
such as IL-17 and IL-1β, activates synovial fibroblasts and induces cytokine 
release (Miossec, 2003). The disruption or blockade of TNF-α pathway 
restrains disease development in multiple arthritis animal models and human 
RA patients (Feldmann et al., 1996). Nowadays, biologic TNF-α inhibitors are 
standard drugs prescribed to treat RA.  
1.6.2.2 IL-6 
IL-6 is a crucial mediator in RA pathogenesis and has multiple functions.  
Both the plasma and synovial fluid level of IL-6 are increased in RA and 
correlated with disease progression (Houssiau et al., 1988; Madhok et al., 
1993). IL-6 contributes to RA development in multiple stages.  
IL-6 regulates the adaptive immunity in RA. IL-6 stimulates the terminal 
differentiation of B cells and their antibody production (Dienz et al., 2009; 
Muraguchi et al., 1988). IL-6 is also a crucial stimulator for differentiation of 
Th17 cells, which are important effectors in synovitis as support by studies 
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with multiple animal disease models (Azizi et al., 2013). Meanwhile, IL-6 
potently suppresses Treg generation, influences Treg stability and interferes its 
suppressive function (Kimura and Kishimoto, 2010; Sarkar and Fox, 2007). 
The inhibition of IL-6 can restore Th17/Treg balance in RA patients (Samson 
et al., 2012).  
IL-6 may mediates the transition from acute to chronic inflammation by 
recruiting monocytes/macrophages (Kaplanski et al., 2003). It was reported 
that IL-6 promotes angiogenesis via VEGF and anti-IL-6R therapy reduces 
VEGF secretion in RA (Dayer and Choy, 2010; Nakahara et al., 2003).  In 
addition, IL-6 can induce expression of chemokines (for example, MCP-1 and 
IL-8) and adhesion molecule (for example, ICAM-1) in endothelial cells, 
which mediated the infiltration of inflammatory immune cells to synovial 
membrane (Hurst et al., 2001; Romano et al., 1997) 
Synovial fibroblasts are one of IL-6 sources and also respond to IL-6 
stimulation, such as their increased proliferation in response to costimulation 
by IL-6 and soluble IL-6R (Mihara et al., 1995). Increasing studies have 
demonstrated that synovial fibroblasts are active players in RA (Huber et al., 
2006).  
In the effector phase of RA, IL-6 contributes to osteoclast formation and bone 
destruction (Kotake et al., 1996; Liu et al., 2005; Wong et al., 2006; Yoshitake 
et al., 2008). Besides, IL-6 is also involved in the development of systemic 
manifestations of RA, such as acute-phase protein synthesis, anemia, systemic 
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osteoporosis and fatigue (Srirangan and Choy, 2010). Humanized monoclonal 
antibody against IL-6R are used in treating moderate to severe RA. 
1.6.2.3 IL-1β 
IL-1β level in both plasma and synovial fluid is elevated in RA patients, and 
displays an association with disease severity (Asehnoune et al., 2014; Kahle et 
al., 1992). Immune complexes, formed by rheumatoid factors, or 
inflammasome activation can trigger IL-1β release by macrophages. Similar to 
TNF-α, IL-1β also upregulates the expression chemokines and CAMs in 
endothelial cells, which directs the infiltration of immune cells to synovial 
membranes (Abbot et al., 1992; Proudman et al., 1999). In addition, IL-1β 
induces the expression of proinflammatory cytokines, prostaglandin, nitric 
oxide and various enzymes by synovial fibroblasts and chondrocytes, which 
contribute to synovitis and joint destruction (Dayer et al., 1986; McDonnell et 
al., 1992). IL-1β plays a similar role as IL-6 in disturbing the Th17/Treg 
balance and favoring inflammation (Ikeda et al., 2014). IL-1β disruption or 
blockade shows beneficial effect in various animal arthritis models (Kay and 
Calabrese, 2004). However, clinical trial of IL-1 receptor antagonist (Anakinra) 
shows unsatisfied efficacy in treating RA patients so far.  
1.6.2.4 GM-CSF 
GM-CSF is named by its ability to promote in vitro granulocytic and 
macrophage colonies from bone marrow precursors and it is usually 
considered as a hematopoietic-cell growth factor. An increasingly body of 
evidence supports GM-CSF as a potent proinflammatory factor in 
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autoimmunity and inflammation, as being extensively reviewed (Hamilton, 
2008; Hamilton, 2015). In RA, GM-CSF is also consider as an emerging 
cytokine target (Burmester et al., 2014). GM-CSF is produced by multiple 
types of cells, such as activated T and B cells, monocytes/macrophages, 
neutrophils, fibroblasts and endothelial cells. GM-CSF receptor is expressed 
on myeloid cells and non-myeloid cells, such as endothelial cells. Thus, GM-
CSF contributes to RA pathogenesis by mobilizing and activating dendritic 
cells, macrophages and neutrophils (Hamilton, 2015). In addition, GM-CSF 
promotes the mobilization of osteoclast precursors but suppresses their 
maturation (Atanga et al., 2011), or promotes the generation of bone-resorbing 
osteoclasts by fusion of mononuclear osteoclasts (Lee et al., 2009).  
Functional studies of GM-CSF in various animal arthritis clearly support an 
essential role of GM-CSF in RA pathogenesis (Campbell et al., 1997; 
Campbell et al., 1998; Hashimoto et al., 2010). Therapeutic approaches 
targeting GM-CSF pathway show significant efficacy in clinical trials with RA 






CHAPTER 2 MATERIALS AND METHODS 
Mice 
Stat3 floxed (Stat3f/f) mice were generated as described (Welte et al., 2003). 
Generation of eTie2-Cre transgenic mouse strain with endothelial-specific 
expression was described (Kano et al., 2003). eTie2-Cre mice were mated with 
Stat3f/f mice to obtain eTie2-Cre; Stat3f/f  (Stat3-/- in short) mice. Stat5f/f mouse 
strain was kindly provided by Dr. Lothar Hennighausen (National Institute of 
Health, USA). Cd4-Cre mouse strain was obtained from Taconic Farms 
(USA). Stat5f/f mice were crossed with Cd4-Cre mice to generate Cd4-Cre; 
Stat5f/f (Stat5-/- in short) mice. CD45.1+ mouse strain was provided by Dr. 
Veronique Angeli (Department of Microbiology, NUS). All mouse strains are 
of C57BL/6 background. All mice used in this study were age- and sex-
matched. All of the animal experiments were conducted in according to 
protocols approved by the Institutional Animal Care and Use Committee 
(IACUC) at the National University of Singapore. 
Mouse genotyping 
Transgenic mouse strains were genotyped by PCR. The last 2 mm of tails were 
cut and lysed with tail lysis buffer supplemented with 1mg/ml Proteinase K 
(Life Technologies) at 56°C for overnight. Proteinase K was heat-deactivated 
by incubating tail lysates at 95°C for 5 min. 1μl of tail lysate was used for one 
PCR reaction by following the manufacture’s instruction (Promega). RCR 




sequences for PCR are as follows: Cre forward, 5’-
CGATGCAACGAGTGATGAGG-3’, and reverse 5’-
CGCATAACCAGTGAAACAGC-3’; Stat3 forward, 5’- 





Lewis lung carcinoma cells (LLC) were kindly provided by Dr. Subhra Biswas 
(Singapore Immunology Network, A-STAR). B16 melanoma cells (B16-F1, 
CRL6323) and mouse endothelial cell line SVEC (SVEC4-10, CRL-2181) 
were purchased from American Type Culture Collection (ATCC, USA). All of 
the cell lines were cultured in DMEM (Sigma) supplemented with 10% FBS 
(Sigma) and under condition with 5% CO2 at 37 °C.  
Subcutaneous tumor model 
To conduct tumor growth model, 5 × 105 LLC cells or 1 × 105 B16 cells in 
100ul PBS were subcutaneously injected into the dorsal flank of Stat3-/- mice 
and control Stat5f/f  (Stat3+/+) mice. Tumor size were measured and calculated 
each day after tumor implantation. Tumor volume was calculated by formula 




Analysis of tumor-infiltrating immune cells 
Tumors were excised at day 14 after cancer cell inoculation. Excised tumors 
were digested with 1mg/ml type II Collagenase (Life Technology, Cat. # 
17101-015) together with 1mg/ml type IV Collagenase (Life Technology, Cat. 
# 17104-019) at 37°C on a rotator for 45 minutes. Undigested large masses 
were excluded by passing digestions through 70 μm cell strainers (BD 
Bioscience). Single cells were then centrifuged and washed one more time. 
Collected cells were incubated with fluorescence-conjugated antibodies 
against surface markers. Flow cytometry was carried out using LSR II 
machine (BD Biosciences). FACS data were analyzed by FlowJo software 
(Tree Star).  
Bone marrow transplantation 
One week before irradiation, recipient mice (Stat3+/+ and Stat3-/- mice) were 
given 0.1 ml oral baytril (oral antibiotics) in 500 ml RO water. On the 
irradiation day, the recipient mice were put in a container for irradiation. The 
irradiator was operated with the standard operating procedure. The mice were 
lethally irradiated with 9 Gy once per individual mouse. After irradiation, 
mice were put back into their original room and subjected to bone marrow cell 
transplantation afterwards. 
Bone marrow cells were isolated from donor mice (CD45.1+ mouse strain) in 
according to standard bone marrow cells isolation protocol. Donor mice were 
euthanized by CO2. Femurs were shaved and dissected to extract the bones. 




DMEM supplemented with 10% FBS (10% FBS/DMEM in short). Cells were 
incubated with red blood cell (RBC) lysis buffer on ice for 5 min to remove 
red blood cells. Bone marrow cells were washed and reconstituted in PBS with 
concentration of 20 million/ ml. 
At 6 hours after irradiation of recipient mice, 100 μl of bone marrow cells (or 
2 million of bone marrow cells) were tail vein injected into recipient mice. RO 
water supplemented with Oral baytril (0.2 mg/ml) was given and changed 
every 3 days. One month later, the efficiency of bone marrow reconstitution 
was examined by analysis of surface marker CD45. The original bone marrow 
cells in recipient mice were CD45.2+ cells. We transferred CD45.1+ bone 
marrow cells to replace original blood cells. The efficiency of bone marrow 
reconstitution was quantified by the percentage of CD45.1+ cells. In our 
experiments, more than 90% of cells were CD45.1 positive. After efficiency 
examination, those recipient mice were used in subcutaneous tumor model, as 
described above. Tumor size were measured and calculated each day after 
tumor implantation. 
Antigen-induced arthritis (AIA) model 
To induce AIA, mice were firstly immunized by subcutaneous injection of 100 
μg methylated bovine serum albumin (mBSA, Sigma) in 100 μl complete 
Freund’s adjuvant (CFA, Sigma) that contained 5 mg/ml heat-killed 
Mycobacterium tuberculosis strain H37Ra (Difco) into two sides on the hind 
flanks at day 0. On day 1, each mouse was intraperitoneally injected with 250 




in 10 μl saline was intraarticularlly injected into the right hind knee joint to 
induce arthritis, while 10 μl saline was intraarticularlly injected into the 
corresponding left hind knee joint as a control. Arthritis progression was 
assessed daily by measurement of joint swelling, which was quantified by the 
difference of diameters between two hind knee joints using a caliper. 
To examine the effect of GM-CSF administration on AIA preogression, when 
inducing AIA, 100 ng GM-CSF (ImmunoTools) together with mBSA were 
intraarticularlly injected into the right hind knee joint as experimental group. 
mBSA alone were injected into the right hind knee joint as control group. To 
assess the effect of GM-CSF and/or TNF-α blockade, anti-GM-CSF (MP1-
22E9, BD Pharmingen) and/or TNF-α (MP6-XT3, BD Pharmingen) 
neutralizing antibodies were intraperitoneally injected at day 6 after 
immunization and day 9 after immunization (or day 2 after AIA induction).  
For AIA induction by adoptive transfer, splenocytes and inguinal lymph node 
cells were isolated from mBSA/CFA-immunized mice at day 7, and cultured 
in vitro with mBSA (10 μg/ml) and IL-7 (2 ng/ml) for 3 days. Cells were 
harvested and incubated with CD4 microbeads (Miltenyi Biotec) to purify 
CD4+ T cells. Flow cytometric analysis demonstrated more than 90% of 
isolated cells were CD4-postive. Those cells were then intravenously 





Collagen-induced arthritis (CIA) model 
The procedure of CIA induction is similar to AIA model. Briefly, mice were 
immunized by 100ug chicken collagen II (Chondrex, Inc) in CFA through 
subcutaneous injection. 250 ng of Pertussis toxin was intraperitoneally 
injected into each mice on the second day. Immunized mice were monitored 
daily. The score system is as follows: 0, no disease indication; 1, mild ankle or 
wrist swelling, or apparent swelling of individual digits; 2, moderate swelling 
of entire paw; 3, severe swelling of entire paw with anchylosis. The sore for 
each mouse was calculated as summed sores for four limbs. 
Primary endothelial cells 
Primary ECs were isolated from murine lung tissues. In brief, lung tissues 
from two-weeks-old pups were harvested and minced. Minced tissues were 
then digested with 1mg/ml type II Collagenase (Life Technology, Cat. # 
17101-015) in HBSS solutions supplemented with 15unit/ml DNase I (Sigma, 
Cat. # D5025) at 37°C on a rotator for 45 minutes. Digested tissues were 
passed through cell strainers (BD Bioscience) and washed to get cell 
suspension. Endothelial cells were enriched by Dynabeads (Life Technology, 
Cat. # 11035) bound with anti-CD31 antibody (BD pharmingen, Cat. # 553370) 
and cultured on 2% collagen pre-coated dish for several days until they 
became confluent. Cells were further purified with Dynabeads coated with 
anti-ICAM2 antibody (BD pharmingen, Cat. # 553326). Isolated ECs were 




(Lonza CC-3162, EC growth medium in short). Half culture medium was 
replaced by fresh medium every other day until cells reaches full conlfuency.  
BMDMs, BMDCs and synovial fibroblasts 
Femurs from mice were dissected to extract the bones. Bone marrow cells 
were flashed out using sterilized syringe and needles with DMEM. Cells were 
incubated with red blood cell (RBC) lysis buffer on ice to deplete red blood 
cells. 
To culture bone marrow-derived macrophages (BMDMs), bone marrow cells 
were reconstituted at concentration of 0.5 million cells per ml with 10% 
FBS/DMEM supplemented with 20 ng/ml M-CSF (R&D systems). 10 ml of 
cell suspension were plated in non-cell culture petridishes. 5 ml of fresh 10% 
FBS/DMEM supplemented with 20 ng/ml M-CSF was added every other day. 
BMDMs were harvested at day 7. Purity of BMDMs were examined by 
staining with CD11b-PE and F4/80-FITC antibodies. More than 98% of cells 
were CD11b+F4/80+, indicating high purity of isolated BMDMs. 
To culture bone marrow-derived dendritic cells (BMDCs), bone marrow cells 
were reconstituted at concentration of 1 million cells per ml with complete 
RPMI (RPMI1640, 10% FBS, 1% PS, 50 μM β-ME) supplemented with 20 
ng/ml GM-CSF (R&D systems). 10 ml of cell suspension was plated in 10 cm 
dish. Culture medium was replaced with fresh medium at day 2 and day 4. 
Cells were left to grow for 4 more days. Cells were harvested by pipetting 
medium over adherent cells, centrifuged, and reconstituted in complete RPMI 




collected on day 10 were mature BMDCs. Purity of BMDCs were checked by 
staining with CD11b-PE and CD11c-APC antibodies. More than 80% of cells 
were CD11bloCD11c+, indicating high purity of isolated BMDCs. 
Synovial fibroblasts were isolated from AIA-induced mice. Synovial tissues 
were dissected from inflamed joints and digested with 1 mg/ml type IV 
collagenase (Life Technology, Cat. # 17104-019) on a rotator at 37°C for 50 
min. Supernatant of tissue digestion was transferred to new tube and 
centrifuged. Cells were reconstituted in 10% FBS/DMEM and plated in 10 cm 
culture dish. Medium was changed every three days. Small pieces of tissues 
were removed from the culture dish after groups of cells were observed under 
a microscopy. Cells were passaged for more than 5 times to obtain synovial 
fibroblasts.  
Protein preparation and western blot 
Adherent cells were washed with PBS. Cells were collected, added with 
Radioimmunoprecipitation assay buffer (RIPA buffer) supplemented with 1× 
protease inhibitor cocktail (Roche) and 1× phosphatase inhibitor cocktail 
(Roche), incubated for 20 min on ice to extract proteins. Cell lysates were 
centrifuged at 12,000 g for 20 min at 4°C to spin down cell debris. Protein 
concentrations were measured by Bio-Rad protein assay and Tecan plate 
reader in according to manufacturer’s recommendation. Equal amounts (20μg) 
of protein extracts in 20μl volume were used for each sample loaded in each 
well. SDS-polyacrylamide gel electrophoresis were performed to separate 




current of 400mA for 90 min. Membranes were then incubated with 5% milk 
in PBST for 1h at room temperature. For protein detecting, membranes were 
incubated with primary antibody with proper dilution overnight at 4°C, 
washed for 3 times with PBST, and incubated with secondary HRP-conjugated 
antibody for 1h at room temperature. chemiluminescent substrates (Thermo 
Scientific) were applied to the membrane. Chemiluminescent signals would be 
detected by film. If additional proteins need to be tested on the same blot, 
membrane would be incubated with stripping buffer (Nacalai Tesque) for 30 
min and then reprobed. Primary antibodies used in this study are listed: 
STAT3 (Santa Cruz, C-20), pY705-STAT3 (Cell Signaling, #9131), STAT5 
(Santa Cruz, C-17), pY694-STAT5 (Cell Signaling, #9151), SELE (Santa 
Cruz, H-300), and beta-Actin (Santa Cruz, C-4). 
RNA preparation and real-time PCR (RT-PCR).  
Cells or tumor tissues were lysed with Trizol. After centrifugation, the 
aqueous phase were added with 70% ethanol and transferred to column from 
RNeasy kit (Qiagen). RNA were extracted in according to the manufacturer’s 
instruction. RNA was converted to complementary DNA (cDNA) using AMV 
reverse transcriptase (Promega) with oligo (dT) primer. To assess the mRNA 
expression of interested genes, reactions were set up with KAPA SYBR FAST 
qPCR kit (KAPA Biosystems). Gene expression levels were assessed by 7500 
real-time PCR system (Applied Biosystems). Samples were normalized using 





Table 1 Primer sequences for real-time PCR. 
Mouse 
Genes 





























































































































































































































































































































Tube formation assay.  
2 × 105 Stat3+/+ and Stat3-/- primary endothelial cells were seeded onto a thin 
layer of growth factor reduced Matrigel (BD biosciences) in 96-well plate. 
Cells were allowed to form tubes for 6 hours. Tubes were examined under 




compare the ability for Stat3+/+ and Stat3-/- endothelial cells to form tubes 
under normal condition, EC growth medium was used in the assay. To test 
whether cancer cell conditioned medium could promote tube formation of 
endothelial cells, EGM-2 basal medium supplemented with 2% FBS (EGM-2 
blank medium in short) was used in the control group and LLC CM was used 
in the experimental group. LLC CM was collected by pre-culture of confluent 
LLC cells with blank medium for 2 days. 
Endothelial cell migration assay.  
5 × 105 LLC cells were seeded in the lower wells of 24-well plates 24h before 
starting of migration assay. Primary endothelial cells were starved in EGM-2 
blank medium for 12h. 2 × 105 Stat3+/+ and Stat3-/- ECs in 200ul EGM-2 blank 
medium were added into Transwell inserts (Corning). LLC cells were changed 
with EGM-2 blank medium and wells were fitted with inserts. Cells were 
allowed to migrate for 16h. The Transwell inserts were then washed with cold 
PBS, fixed with formaldehyde and stained with crystal violet. The un-migrated 
cells were carefully swiped with a cotton swap. Migrated cells were examined 
under microscopy. Cell counting of migrated cells was performed by ImageJ. 
Treg adhesion assay 
2 × 105 Stat3+/+ and Stat3-/- primary endothelial cells were plated in 96-well 
that pre-coated with 2% gelatin. ECs were pre-treated with 20μg/ml TNF-α for 
24 hours to upregulate expression of adhesion molecules. Culture medium was 
changed just before adhesion assay. CD4+CD25+ Treg cells were sorted out 




Technology) in 0.1% BSA/PBS at 37°C for 15 min. 4 × 105 CFSE-labeled 
Treg cells were layered onto the endothelial monolayer. 2 hours after 
incubation, wells were gently wash with PBS for 3 times to remove non-
adherent Treg cells. Adherent Treg cells were observed under fluorescence 
microscopy. Cell counting of adherent cells was carried out by ImageJ 
software.  
Neutrophil transendothelial migration assay 
SVEC cells were trypsinized and centrifuged to obtain cell pellet. 2 × 104 
SVEC cells in 200 μl 10% FBS/DMEM were plated in inserts of Transwell 
systems (Corning).  
Neutrophils were isolated from spleens. Splenocytes were lysed with RBC 
lysis buffer to remove red blood cells. CD11b+Gr-1+ neutrophils were sorted 
out by FACS Aria (BD Bioscience). Neutrophils were incubated with 
CellTrace CFSE dye (Life Technology) in 0.1% BSA/PBS at 37°C for 15 min 
and washed with PBS. 1.5 × 105 CFSE-labeled neutrophils in 250 μl RPMI 
supplemented with 10% FBS (10% FBS/RPMI for short) were added into 
inserts. 10% FBS/RPMI with or without 20ng/ml GM-CSF were added into 
the lower wells of the plate. Neutrophils were allowed to migrate for 3 hours. 
Cells that trans-endothelial migrated into the lower wells were counted and 
observed under fluorescence microscopy. 
Flow cytometry  
Spleens and LNs were minced and passed through 70-μm cell strainers. Single 




cells. Synovial membranes were dissected from AIA mice at indicated time 
points and incubated in cRPMI medium (RPMI 1640 + 10% FBS + 1% PS + 
50 μM β-ME) with 1 mg/ml collagenase IV (Invitrogen) and 0.1 mg/ml DNase 
I (Sigma) for 45 min at 37°C, followed by passing through 70-μm cell 
strainers.  
Single cell suspensions were washed, preincubated with Fc block (BD 
Pharmingen), and then incubated with indicated fluorescence-conjugated 
antibodies for staining surface markers. Sytoxblue was added just before cells 
were acquired on the LSR II instrument (BD Biosciences).  
For intracellular cytokine staining, single cell suspensions from spleens, LNs 
or synovial membranes were stimulated in cRPMI with 50 ng/ml phorbol 12-
myristate 13-acetate (PMA, Sigma) and 500 ng/ml ionomycin (Sigma) in the 
presence of Golgiplug (BD Biosciences) for 4 h. In the case of antigen 
restimulation, splenocytes and LNs were incubated with mBSA (20 μg/ml) in 
cRPMI medium for 24 h with the addition of Golgiplug in the last 4 h. Cells 
were first stained for antibodies against surface markers and with Live/Dead 
Fixable Violet Blue dye (Invitrogen), and thereafter fixed and permeabilized 
with a Cytofix/Cytoperm kit (BD Pharmingen) according to manufacturer’s 
recommendation, followed by intracellular staining for GM-CSF, IL-17 and 
IFN-γ. Cells were acquired on the LSR II and analyzed with FlowJo software 




Neutrophil apoptosis detection 
To assess the effect of GM-CSF on neutrophil apoptosis, neutrophils were 
sorted from murine spleens and cultured with or without 20 ng/ml GM-CSF 
for 24 h. Neutrophils were then co-stained with Annexin V and Propidium 
Iodide (PI) using Annexin V apoptosis detection kit from BD Bioscience. 
Cells were acquired on the LSR II. 
Immunofluorescence staining 
To examine tumor vessel density, tumors were excised and fixed with 4% 
Paraformaldehyde, followed by dehydrating in 30% Sucrose. Dehydrated 
samples were then embedded in OCT (Tissue-Tek) and snap frozen on dry ice. 
Sections (20um) were air-dried, washed with 0.1% Triton/PBS for 3 times, 
and stained with rat anti-mouse CD31 antibody (BD pharmingen), followed by 
incubation with Alexa Fluor 568-conjugated goat anti-rat IgG (H+L) 
secondary antibody (Invitrogen). The pixel counting to evaluate vessel density 
was performed by ImageJ.  
Detection of tumor hypoxia 
To detect tumor hypoxia levels, Hypoxyprobe-1 Plus Kit (Chemicon 
International) was used. Hypoxyprobe (pimonidazole hydrochloride) is stable, 
water soluble, and able to diffuse readily into both tumors and normal tissues. 
Hypoxyprobe-1 primary FITC-conjugated mouse monoclonal antibody (Mab) 




At day 14 after tumor cells injection, tumor-bearing mice were intraarticularlly 
injected with Hypoxyprobe-1 in 0.9% saline at dosage of 60 mg/kg body 
weight. Mice were euthanized by CO2 one hour after Hypoxyprobe-1 injection. 
Tumors were excised and processed for immunofluorescence staining. 
Sections were stained with Hypoxyprobe-1 FITC-conjugated monoclonal 
antibody and rat anti-mouse CD31 antibody (BD pharmingen), followed by 
incubation with Alexa Fluor 568-conjugated goat anti-rat IgG (H+L) 
secondary antibody (Invitrogen). Cell nucleus was stained with DAPI (Sigma).  
Tissue processing for histology 
Knee joints or paws were excised and fixed in 10% formalin/PBS for 3 days at 
4°C. Bones were then decalcified in 5% formic acid for several days (~5 days). 
Tissues were processed to dehydration with a series of graded ethanol (70%, 
80%, 95%, 100%, 100% ethanol for 1 hour each step) to replace water. 
Tissues were then cleared with two changes of Histoclear (National 
Diagnostics, 1 hour per change). Clear reagent was replaced with 1:1 
Histoclear:wax for 1 hour infiltration at 58°C. Tissues were infiltrated with 
100% paraffin wax, embedded with paraffin wax, and proceeded for 
sectioning.  
Sectioning was carried our using a microtome (Thermo Scientific). Sections 
were de-waxed by 3 changes of 100% Histoclear (10 min per change), 
followed by re-hydration with a series of graded ethanol (from 100% ethanol 




hydrated sections were preceded to either hematoxylin and eosin staining or 
Safranin-O/Fast Green staining. 
Haematoxylin and eosin (H&E) staining 
Re-hydrated sections (10 μm) were stained with haematoxylin for 4 min and 
washed with water. Sections were dipped in 0.3% acid alcohol for seconds and 
washed with tap water. Slides were then stained with eosin for 2 min, washed 
with water, dehydrated with a series of graded ethanol (from 70% ethanol to 
85% ethanol, and to 100% ethanol), cleared by Histoclear, and mounted by 
DPX mountant (Sigma).  
Safranin-O/Fast Green staining  
To assess cartilage depletion, re-hydrated sections (10 μm) were stained with 
0.02% Fast Green dye (Sigma) for 1 min, dipped in 0.3% acid alcohol for 30 
seconds, and stained with 1.0% Safranin O dye (Sigma) for 20 min. Sections 
were then dehydrated with 2 changes of 95% ethanol and 2 changes of 100% 
ethanol. Dehydrated sections were then cleared and mounted.  
May Grunwald-Giemsa Stain 
Ly6ChiLy6G- population and Ly6CloLy6Ghi population gated on 
CD45+CD11b+ were sorted with FACS Aria (BD Bioscience) from synovial 
single cell suspensions. Load 200 μl sorted cells into cuvette of Cytoslides 
(Shandon Inc.) and centrifuge at 800 rpm for 3 min with Cytospin 
Cytocentrifuge (Thermo Scientific). Carefully detach cuvette from slides. Dip 




diluted May-Grunwald’s staining buffer (Merck, Cat. #1424) for 6 min. Rinse 
slides with water to remove unstained dye. Stain slides with freshly diluted 
Giemsa solution (Merck, Cat. #9204) for 7 min. Air dry water washed slides 
and mount them with DPX mountant (Sigma). Observe cell morphology under 
microscopy.  
Statistics.  
Statistical analysis was performed on GraphPad Prism with student’s t test. p 
value <0.05 was viewed as significant. Data were presented as mean and 





CHAPTER 3 ROLE OF ENDOTHELIAL STAT3 IN TUMOR 
DEVELOPMENT 
3.1 Introduction 
Remarkable progress in cancer research expands our understanding of traits 
that enable tumor growth and metastasis, including eight hallmarks namely 
sustained cell proliferation, resistance to apoptosis, tumor angiogenesis, 
replicative immortality, tumor metastasis, insensitivity to growth suppressors, 
reprogramming cellular metabolism and immune evasion, and two enabling 
characteristics including genome instability and tumor-promoting 
inflammation (Hanahan and Weinberg, 2011). Of note, it is now known that 
tumor microenvironment must be encompassed in elucidation of tumor growth 
and metastasis. Tumor angiogenesis and tumor immune evasion are of 
particular interest that illustrate the complex interactions within tumor 
microenvironment, and foster tumor growth and metastasis.  
Tumor angiogenesis is the process of abnormal blood vessel formation inside 
tumors, which was proposed as a requirement for tumor growth and metastasis 
four decades ago (Folkman, 1971). The tumor-associated vasculature, which 
are formed by endothelial cells, is permissive for growth or expansion of 
tumor mass, because it delivers required oxygen and nutrients to tumor cells 
(Carmeliet and Jain, 2000). Angiogenesis and tumor invasion are closely and 
functionally related (Liotta et al., 1991). Tumor metastasis consists of multiple 




provides a route for tumor cell escape (Chambers et al., 2002). Thus, in those 
metastatic cancers, cancer cells can enter and circulate through the blood 
vessels to arrive in other organs. Given the importance of angiogenesis in 
tumor growth and metastasis, over the past decade, tremendous efforts are 
spent in elucidating the regulatory mechanism of angiogenesis. As being 
reviewed elsewhere (Carmeliet and Jain, 2011a; Weis and Cheresh, 2011), the 
tumor microenvironment contains plenty of molecules and components, acting 
as either angiogenic stimulators or suppressors, which influence angiogenesis 
process. Knowledge from angiogenesis research has given rise to promising 
targets and approaches for therapeutic intervention of cancer. Hundreds of 
thousands of cancer patients have benefited from anti-angiogenesis drug 
therapy, since the approval of bevacizumab as the first clinical inhibitor of 
tumor angiogenesis by Food and Drug Administration (FDA) (Ferrara et al., 
2004). However, the problem of limited efficiency and drug resistance remains. 
Further studies of signaling pathways that control tumor angiogenesis within 
tumor microenvironment may shed new light on addressing this problem. 
Tumor immune evasion is an emerging hallmark of cancer that is under 
extensive exploration in recent years. Immune system serves as surveillance 
that monitors and eliminates tumorigenic cells or nascent tumor cells in early 
host defense. Accumulated studies evidenced immune surveillance in 
preventing and eradicating cancer (Vesely et al., 2011). For instance, 
genetically modified immunodeficient mice grow more tumors and/or have 
more rapidly enlarged tumors than immunocompetent mice (Teng et al., 2008). 




destruction via inhibiting anti-tumor immunity in versatile ways. For example, 
immunosuppressive cells, including Treg cells and MDSCs, in the tumor 
microenvironment can directly reduce the activity of cytotoxic lymphocytes 
and therefore help tumor cells to escape eradication (Mougiakakos et al., 2010; 
Ostrand-Rosenberg and Sinha, 2009). For another example, TAMs with a 
specific gene signature and potent ability in promoting tumorigenesis via both 
non-immune and immune mechanisms, such as promoting angiogenesis, 
facilitating tumor cell invasion and suppressing T cell activation as 
demonstrated by extensive literature (Gabrilovich and Nagaraj, 2009). The 
immune system can either defend against or promote tumor progression, the 
dual actions usually referred to as cancer immunoediting, supported by 
numerous investigations (Schreiber et al., 2011; Vesely et al., 2011). 
Understanding how the immune components and immune responses are 
specified for anti-tumor immunity versus tumor promotion is a challenging 
question at the crossroad of immunology and cancer biology.  
Besides as components of tumor vasculature, endothelial cells act as regulators 
of immune cell functions, for instance by modulating immune cell recruitment 
and by directly affecting immune response (Motz and Coukos, 2011). 
Accumulating evidence suggests that tumor angiogenesis and tumor immune 
evasion within tumor microenvironment frequently occur simultaneously 
(Motz and Coukos, 2013). That is one key reason why we take these two 
processes into consideration together.  
A tumor cell-intrinsic role of STAT3 signaling pathway in tumor progression 




oncogenesis by several studies. STAT3 was first found constitutively activated 
in cells that transformed by oncoprotein SRC (Yu et al., 1995). A more direct 
and convincing evidence is that a STAT3 mutant with constitutive activation 
has the ability to transform fibroblasts and enables them to form tumor mass in 
immunodeficient mice (Bromberg et al., 1999). Persistently activated STAT3 
contributes to tumor progression in multiple ways: it promotes tumor cell 
survival by upregulating anti-apoptotic molecules such as Bcl-xL (Catlett-
Falcone et al., 1999) and Mcl-1 (Epling-Burnette et al., 2001); it renders 
cancer cell high proliferation by upregulating cell cycle-related genes such as 
Cyclin D1 (Masuda et al., 2002) and c-myc (Kiuchi et al., 1999); it facilitates 
cancer cell invasion by upregulating the expression level of metastatic genes 
such as MMP-1 (Itoh et al., 2006) and MMP-2 (Xie et al., 2004), and enhances 
tumor angiogenesis as a potential transcriptional regulator of VEGF (Niu et al., 
2002). 
STAT3 activity in endothelial cells during tumor development, a tumor cell-
extrinsic role of STAT3, is less studied. In a study of human brain tumors, 
constitutively activated STAT3 was found to predominantly localize to tumor 
endothelium (Schaefer et al., 2002). Endothelial-specific STAT3 activation in 
brain tumors may facilitate autocrine VEGF activation (Schaefer et al., 2002). 
Immunohistology analysis also suggest that the level of activated STAT3 was 
at limited in endothelium of normal mouse organs but was dramatically 
induced in endothelium of different mouse tumors (Lassoued et al., 2010). It is 
also shown that STAT3 is phosphorylated in bFGF-induced proliferation of 




the translocation of phosphorylated STAT3 blocks VEGF-mediated migration 
and tube formation of human ECs (Yahata et al., 2003). Similarly, blocking 
activation of STAT3 in ECs affected the migration and vessel formation of 
ECs upon tumor-derived factor stimulation (Kujawski et al., 2008). Moreover, 
endothelial deficiency of SOCS3, a negative regulator of STAT3 activation, 
leads to enhanced pathogenic neovascularization and increased tumor size, 
suggesting that SOCS3 acts as an endogenous suppressor for pathogenic 
angiogenesis (Stahl et al., 2012). In summary, most studies discussed above 
are performed with in vitro system or are phenotypic descriptions. 
Nevertheless, those indicative evidence supports a potential role of EC-
specific STAT3 in mediating EC activity as well as tumor development, but 






3.2.1 Tumor cell-derived soluble factors strongly activate endothelial STAT3 
Activation of STAT3 has been reported in ECs lining tumor vessels in 
histology analysis of human as well as mouse tumor specimens (Couto et al., 
2012; Kujawski et al., 2008). We hypothesized that tumor-derived soluble 
factors could stimulate the activation of STAT3 in ECs within tumor 
microenvironment. To test this hypothesis, primary ECs were isolated and 
examined in response to stimuli with cancer cell conditioned medium.  
Primary ECs were isolated from murine lung tissues according to a two-step 
purification procedure. In brief, CD31+ cells were sorted by Dynabeads pre-
coated with anti-CD31 antibody and cultured for days to reach confluency. 
Then, ECs were subjected to second purification by Dynabeads pre-coated 
with anti-ICAM/CD102 antibody and subsequently cultured. Isolated ECs in 
vitro showed uniformed and typical cobblestone morphology under light 
microscopy (Figure 3-1a). Immunostaining of EC-specific marker CD31 
showed majority of cells were CD31-positive, indicating high purity of 
isolated ECs (Figure 3-1b).  
Lewis lung carcinoma (LLC) and B16 melanoma cells were used to prepare 
cancer cell conditioned medium (C.M.). Primary ECs were then stimulated 
with C.M. (IL-6 as positive control) at various time points. As shown in Figure 
3-1c, the treatment with either LLC or B16 C.M. induced STAT3 activation, 
as examined by specific antibody against phosopho-STAT3 (Tyr705) in 




after C.M. stimulation, and moreover STAT3 activation lasted longer than 2 h 
(Figure 3-1c). No obvious difference in total protein level of STAT3 was 
observed over 2 h course of treatment (Figure 3-1c). This result indicates that 
certain soluble factors secreted by cancer cells are able to induce a potent and 
persistent activation of STAT3 in ECs, thus suggesting a potential role of 
endothelial cell-specific STAT3 (or endothelial STAT3) in responding to 
tumor development. Therefore, we next studied the exact role of endothelial 
STAT3 in tumor progression in vivo. 
 
Figure 3-1 Tumor cell-derived soluble factors strongly activate STAT3 in 
primary ECs. 
(a) Representative image of purified and cultured primary ECs under light 
microscope.  
(b) Representative confocal fluorescence image of primary ECs stained with 
anti-CD31 antibody.  
(c) The expression of pSTAT3 (Y705), STAT3 and Actin in primary ECs 
untreated or treated with LLC C.M., B16 C.M. or IL-6 for indicated time were 




3.2.2 Loss of STAT3 in ECs suppresses tumor development 
Our lab has developed a transgenic (eTie2-Cre) mouse strain with Cre 
recombinase expression specifically in endothelium (Kano et al., 2003). This 
mouse strain was crossed with Stat3 floxed (Stat3f/f) mouse strain to obtain 
eTie2-Cre; Stat3f/f  (Stat3-/- in short) mice, in which STAT3 was specifically 
deleted in endothelium.  
To test if endothelial STAT3 is involved in tumor progression in vivo, a wildly 
used subcutaneous tumor model was employed in the following studies. LLC 
cells were subcutaneously injected to Stat3-/- mice and control littermates 
(Stat3+/+). Visible tumor masses were observed in Stat3+/+ mice at day 9 after 
tumor inoculation, whereas no obvious tumor masses were observed in all 
Stat3-/- mice at that time (Figure 3-2a). Visible tumor masses were only 
observed in Stat3-/- mice at day 11 after tumor inoculation (Figure 3-2a). The 
size of tumors were measured daily and calculated as ½ × length × width2. 
Visible tumors grew quickly in Stat3+/+ mice over time (Figure 3-2a). In 
contrast, tumors from Stat3-/- mice were dramatically and persistently smaller 
than those from Stat3+/+ mice (Figure 3-2 a and b).  
To check if this finding is also applied to other tumor types, we repeated this 
experiment with B16-F10 tumor cells, widely used murine melanoma cells. 
Consistently, subcutaneous inoculation of B16 melanoma cells also formed 
smaller tumor masses in Stat3+/+ mice than in Stat3-/- mice (Figure 3-2 c and d). 




suppresses tumor growth, supporting an essential role of endothelial STAT3 in 
promoting tumor development. 
 
Figure 3-2 Loss of STAT3 in ECs suppresses tumor development. 
(a) Tumor growth curve of LLC inoculation. Stat3-/- mice and littermate 
control (Stat3+/+) (n=8) were subcutaneously inoculated with 0.5 million of 
LLC cells. Tumor volumes were observed and measured daily after tumor 
inoculation. Tumor volume was determined by ½ × length × width2. Data 
represents five independent experiments. 
(b) Representative images of dissected tumors at day 16 after LLC inoculation. 
(c) Tumor growth curve of B16 inoculation. Stat3-/- mice and their control 
littermates (Stat3+/+) (n=3) were subcutaneously inoculated with 5× 105 B16 
cells. Tumor volumes were observed and measured daily after tumor 
inoculation. Tumor volume was determined by ½ × length × width2. Data are 
representative of two independent experiments. 






3.2.3 Stat3-/- mice reconstituted with wild type bone marrow have reduced 
tumor burden 
The eTie2-Cre transgenic mouse strain was generated by using Tie2 promoter 
and an enhance element from first intron, which restricts Cre expression in 
endothelium (Kano et al., 2003). It has been reported that Tie2-Cre transgenic 
(2.1 kb Tie2 promoter + 10.5 kb first intron) mouse strain express Cre 
recombinase in both endothelium and hematopoietic cells (Constien et al., 
2001). When our eTie2-Cre strain was mated with Z/EG reporter mice that 
produce GFP by Cre-mediated recombination, vast majority of GFP 
expression was observed in endothelium, whereas in only a minimal 
percentage (~1.5%) of bone marrow cells (Kano et al., 2003). To fully exclude 
any possible effect due to minor STAT3 deletion in bone marrow cells in 
subcutaneous tumor assay, we reconstituted bone marrow of eTie2-Cre; 
Stat3f/f (or Stat3-/- in short) mice and littermate control (Stat3+/+) with STAT3 
wild type bone marrow before tumor inoculation (Figure 3-3a). 
Stat3+/+ and Stat3-/- mice were lethally irradiated and subsequently 
transplanted with 2 million of bone marrow cells isolated from CD45.1+ 
mouse strain at 6 hours after irradiation. One month later, the efficiency of 
bone marrow reconstitution was examined by analysis of surface marker 
CD45. The endogenous bone marrow cells in recipient (Stat3+/+ and Stat3-/-) 
mice were CD45.2+ cells, but the transferred bone marrow cells were CD45.1-
positive. Efficiency of bone marrow reconstitution was quantified by the 
percentage of CD45.1+ cells among peripheral blood mononuclear cells 




mice were CD45.1 positive in a dramatic contrast to that less than 2% cells are 
CD45.2 positive, indicating high efficiency of bone marrow reconstitution. In 
addition, no significant difference of reconstitution efficiency between Stat3+/+ 
and Stat3-/- mice was observed (Figure 3-3c). 
After reconstitution efficiency test, those recipient mice were subcutaneously 
injected with LLC cells and monitored as previously described. Stat3-/- mice 
reconstituted with wild type bone marrow developed reduced tumor volume in 
comparison to reconstituted Stat3+/+ mice (Figure 3-3d and e). This result 
clearly supports that endothelium-specific deletion of STAT3 impairs tumor 
progression in mice. How endothelial STAT3 regulates tumor development 
was subsequently investigated.  
Legend of figure 3-3 Stat3-/- mice reconstituted with wild type bone marrow 
have reduced tumor burden. 
 (a) Schematic diagram of bone marrow transplantation and subsequent tumor 
inoculation. Stat3+/+ and Stat3-/- mice were lethally irradiated at 9Gy per 
mouse and transplanted with 2 million bone marrow cells isolated from 
CD45.1+ mouse strain that express wild type STAT3. Mice were housed for 
one month to allow complete replacement of bone marrow. The efficiency of 
bone marrow reconstitution was quantified by the percentage of CD45.1+ cells 
in peripheral blood mononuclear cells (PBMCs) of recipient mice. LLC 
inoculation was performed in recipient mice 30 days after bone marrow 
transplantation. 
(b) Representative flow cytometry of CD45.1+ and CD45.2+ cells among 
PBMCs of recipient mice. 
(c) Percentage of CD45.1+ cells in PBMCs of recipient mice (n=5).  
(d) Tumor volumes of Stat3+/+ and Stat3-/- mice reconstituted with wild type 
bone marrow at day 16 after LLC inoculation (n=5). 
(e) Representative image of dissected tumors at day 16 after LLC inoculation. 
 All data shown are representative of two independent experiments. 






Figure 3-3 Stat3-/- mice reconstituted with wild type bone marrow have 
reduced tumor burden. 




3.2.4 Tumor angiogenesis is dampened by STAT3 deletion in endothelium 
Newly formed endothelial cell-lining blood vessels are required for tumor 
growth (Folkman, 1971). The tumor-associated vasculature is permissive for 
growth or expansion of tumor mass, as it delivers required oxygen and 
nutrients to tumor cells (Carmeliet and Jain, 2000). To study if endothelial 
STAT3 regulates tumor angiogenesis, tumors from Stat3-/- and Stat3+/+ mice 
were dissected to examine tumor vessel density. Then tumors were sectioned 
and stained with antibody against endothelial marker CD31/PECAM to 
visualize blood vessels. Interestingly, tumors from Stat3-/- mice showed a 
marked reduction of tumor vessel density, in comparison to tumors from 
Stat3+/+ mice (Figure 3-4a and b). 
Aberrant tumor vessels and chaotic blood flow cause hypoxia in tumors 
(Harris, 2002). Hypoxia is toxic to tumor cells. However, tumors utilize 
various pathways to survive and progress in hypoxic conditions. For instance, 
hypoxia induces the production of growth factors that promote tumor 
angiogenesis (Harris, 2002).  
To detect tumor hypoxia levels within tumors engrafted in Stat3+/+ and Stat3-/- 
mice, a reagent called Hypoxyprobe-1 (pimonidazole hydrochloride) was 
injected into tumor-bearing mice intraperitoneally. Pimonidazole 
hydrochloride is stable and water soluble, which is able to diffuse readily into 
both tumors and normal tissues. In hypoxia cells, pimonidazole is reductively 
activated. The reductively activated pimonidazole adducts can be recognized 




Thus, hypoxic areas can be visualized in tumor sections. After the injection of 
Hypoxyprobe-1 for 1 h, tumors were excised and tumor frozen-sections were 
stained accordingly. As shown in Figure 3-4c and d, tumors from Stat3-/- mice 
experienced much higher hypoxia than tumors from Stat3+/+ mice. Notably, 
increased level of hypoxia in tumors from Stat3-/- mice failed to induce 
sufficient blood vessels (Figure 3-4c), suggesting that loss of STAT3 in 
endothelium may disrupt hypoxia-induced responses. 
HIF1 pathway is essential for hypoxia-induced angiogenesis (Harris, 2002). 
Under hypoxic conditions, HIF-1α is stabilized and then regulate transcription 
of angiogenesis-related genes. We found that the mRNA level of HIF-1α was 
reduced in STAT3-deficient ECs (Figure 3-4e). Treatment with hypoxia-
mimetic CoCl2 induced stabilization of HIF-1α in SVEC (Figure 3-4f). 
Pretreatment with 10 μg/ml Stattic, a STAT3 inhibitor, suppressed CoCl2-
induced stabilization of HIF-1α (Figure 3-4f), indicating that STAT3 is 
required for HIF-1α stabilization in ECs. It has been reported that HIF-1α-
deficient ECs have reduced hypoxia-induced tube formation (Tang et al., 
2004). In addition, mice with endothelium-specific deletion of HIF-1α 
developed reduced tumor vessels and smaller tumors (Tang et al., 2004). 
Therefore, unresponsiveness to hypoxia in tumors from STAT3-deficient mice 
might due to suppressed HIF-1α pathway in Stat3-/- ECs. 
We also observed reduced expression of VEGFR-2, also known as Flk-1, on 
both mRNA level and protein level (Figure 3-4g and h). VEGFR-2 is the main 
receptor for VEGF to exert its pro-angiogenic effect on ECs. Signals through 




(Shibuya and Claesson-Welsh, 2006). A recent report demonstrated that 
expression of VEGFR-2 in tumor-associated ECs was regulated by STAT3 
(Lee et al., 2015). Knockdown of VEGFR-2 by siRNA suppressed tube 
formation of ECs (Lee et al., 2015). Hence, reduced expression of VEGFR-2 
in STAT3-deficient ECs may partially explain dampened tumor angiogenesis 
in Stat3-/- mice. 
Legend of figure3-4 Lower blood vessel density in tumors engrafted in Stat3-/- 
mice.  
(a) Representative confocal images of blood vessels in LLC tumors from 
Stat3+/+ and Stat3-/- mice.  
(b) Statistics of blood vessel density as in a (n=3). Data are representative of 
three independent experiments. 
(c) Representative confocal images of hypoxia detection by staining against 
Pimonidazole adducts in tumors from Stat3+/+ and Stat3-/- mice. 
(d) Statistics of areas of hypoxia in tumors from Stat3+/+ and Stat3-/- mice 
(n=4). Data are representative of two independent experiments. 
(e) mRNA expression of HIF-1α in Stat3+/+ and Stat3-/- ECs. 
(f) Protein levels of HIF-1α and Actin in SVEC were assessed by western blot. 
SVEC were treated with hypoxia-mimetic CoCl2 for 2 or 4 h to induce 
stabilization of HIF-1α. Cells were pretreated with Stattic to inhibit activation 
of STAT3. 
(g) mRNA expression of VEGFR-2 in Stat3+/+ and Stat3-/- ECs. 
(f) Protein levels of VEGFR-2 and Actin in primary ECs were assessed by 






Figure 3-4 Lower blood vessel density in tumors engrafted in Stat3-/- mice.  




3.2.5 STAT3-deficient ECs have reduced tube formation and migration ability 
in response to tumor-secreted soluble factors 
Tube formation assay and EC migration assay are widely used to study 
angiogenesis in vitro. To test whether deletion of STAT3 interferes the tube 
formation and migration abilities of ECs, Stat3+/+ and Stat3-/- primary ECs 
were therefore isolated and tested. Western blot analysis showed that STAT3 
was completely abrogated in Stat3-/- ECs (Figure 3-5a). When cultured ECs 
were supplied with sufficient growth factors (using complete growth medium 
from Lonza), there was no obvious difference in tube formation on Matrigel 
between Stat3+/+ and Stat3-/- ECs (Figure 3-5b and c), which is consistent with 
a previous report that showed no defect in tube formation of STAT3-deficient 
ECs (Kano et al., 2003). 
Next, I examined tube formation ability of ECs in response to tumor-secreted 
soluble factors. For control groups, blank medium (supplemented with 2% 
FBS without additional growth factors) was used. For experimental groups, 
LLC C.M. was prepared by incubation of confluent LLC cells with blank 
medium for 2 days. As shown in Figure 3-5 d and e, under blank medium 
condition, both Stat3+/+ and Stat3-/- ECs formed limited but comparable tubes 
on Matrigel. Nevertheless, the presence of LLC C.M. obviously promoted tube 
formation of Stat3+/+ ECs but not Stat3-/- ECs (Figure 3-5d and e). 
Transwell system was utilized in the assessment of migration ability of wild 
type versus STAT3-deficient ECs. LLC cells were plated in the lower wells to 




membrane of inserts. Stat3+/+ and Stat3-/- ECs, pre-starved with blank medium, 
were seeded in the inserts and allowed to migrate for 16 hours before detection. 
Migrated ECs were detected in both groups, but in comparison to Stat3+/+ ECs, 
Stat3-/- ECs showed impaired migration potential upon stimulation by tumor 
cell-secreted factors (Figure 3-5f and g).  
In summary, the above results demonstrated that STAT3-deficient ECs have 
reduced in vitro tube formation and migration ability in response to tumor cell-
derived factors, suggesting that deletion of STAT3 in ECs may cause defects 
in tumor angiogenesis. The molecular mechanisms underlying endothelial 
STAT3-regulated angiogenesis would be further investigated.  
Figure 3-5 Defective tube formation and migration ability of STAT3-deficient 
ECs in response to tumor-secreted soluble factors. 
(a) Western blot analysis of STAT3 and Actin expression in Stat3+/+ and 
Stat3-/- ECs. 
(b and c) Representative images (b) and statistics (c) of tube formation of 
Stat3+/+ and Stat3-/- ECs under complete growth medium supplemented with 
sufficient growth factors. Data are representative of three independent 
experiments. 
(d and e) Representative images (d) and statistics (d) of tube formation of 
Stat3+/+ and Stat3-/- ECs under conditions of blank medium without growth 
factors and LLC C.M. Data are representative of two independent experiments. 
(f and g) Representative images (f) and statistics (g) of transmigrated Stat3+/+ 
and Stat3-/- ECs in response to tumor cell-derived soluble factors. Data are 
representative of two independent experiments. 






Figure 3-5 Defective tube formation and migration ability of STAT3-
deficient ECs in response to tumor-secreted soluble factors.   




3.2.6 Chemokine profile in LLC tumors 
Accumulating evidence now suggests that, in addition to its role in supplying 
nutrients and oxygen, tumor endothelium also acts as an active barrier that 
regulates extravasation of immune cells to reach the core of tumors (Boon et 
al., 2006; Lurquin et al., 2005). Immune cells need to circulate to and 
extravasate tumor vasculature to exert their anti-tumor or tumor promoting 
functions. Chemokines and their corresponding receptors are essential for 
immune cell trafficking to tumor microenvironment (Franciszkiewicz et al., 
2012).  
To determine whether the deletion of endothelial STAT3 alters the expression 
pattern of chemokines and chemokine receptors in tumors, LLC tumor masses 
that grew in Stat3+/+ and Stat3-/- mice were dissected and lysed to extract 
mRNA for RT-PCR analysis. We designed primers for profiling chemokines 
and chemokine receptors, including CC and CXC groups. As results shown in 
Figure 3-6, the expression levels of several chemokines and chemokine 
receptors were selectively decreased in tumors from Stat3-/- mice.  
For instance, the expression of CCL1 (Tiffany et al., 1997) and its receptor 
CCR8 (Roos et al., 1997) were significantly reduced (Figure 3-6a and b). 
CCL1 has been linked to Treg conversion and suppressive functions 
(Hoelzinger et al., 2010). Blockade of CCL1 enhances the anti-tumor effects 
of toll-like receptor (TLR) ligand treatment in an endogenous mouse tumor 
model, leading to tumor rejection and prolonged survival, which are correlated 




al., 2010). CXCL16 and its specific receptor CXCR6, which were decreased in 
tumors from Stat3-/- mice (Figure 3-6c and d), have also been reported to 
localize Treg cells to nasopharyngeal carcinoma (Parsonage et al., 2012). 
CCL3/MIP-1α (macrophage inflammatory protein-1α) (Cook, 1996), 
CCL4/MIP-1β (Bystry et al., 2001), CCL5/RANTES (regulated on activation, 
normal T cell expressed and secreted) (Schall, 1991), and CCL8/MCP-2 
(monocyte chemoattractant protein 2) (Proost et al., 1996) are monocytes-
attracting chemokines.  
The differential expression of chemokines in tumor microenvironment may 
permit selective infiltration of certain immune cells. The changes in 
chemokine and chemokine receptor profile observed here may implicate an 
alteration in composition or abundance of various tumor-infiltrating immune 





Figure 3-6 Chemokine profile in LLC tumors   
(a to d) Relative mRNA expression levels of chemokine (C-C motif) ligands 
(a), chemokine (C-C motif) receptors (b), chemokine (C-X-C motif) ligands 
(c), and chemokine (C-X-C motif) receptors (d) in LLC tumors from 
endothelial STAT3-deficient mice versus wild type mice (n=2 per group). 
PCR data was normalized to Gapdh. Gene expression in LLC tumors from 
wild type mice was set to 1.  





3.2.7 Treg infiltration is selectively decreased in tumors with endothelial 
STAT3 deletion. 
Tumor-infiltrating immune cells are essential for regulating tumor progression 
and regression. Different immune cell populations may exert opposing roles in 
tumor development: mediating tumor rejection by eliminating neoplastic cells 
or supporting tumor growth by suppressing anti-tumor immunity (Schreiber et 
al., 2011). We speculated that analysis of tumor-infiltrating immune cell 
populations may help to explain the suppressed tumor growth in endothelial 
STAT3-deficient mice. 
In order to analyze tumor-infiltrating immune cells, LLC tumors grew in 
Stat3+/+ and Stat3-/- mice were excised and digested into single cells for flow 
cytometry. As shown in Figure 3-7a, tumors from Stat3+/+ and Stat3-/- mice 
showed similar percentages of infiltrated leukocytes (CD45+ cells). Myeloid 
DCs positive for surface markers CD11b and CD11c exhibited comparable 
percentages in tumors from Stat3+/+ and Stat3-/- mice (Figure 3-7b). Analysis 
of tumor-infiltrating lymphocytes (TILs) also showed similar percentages of 
CD4+ T cells as well as CD8+ T cells in tumors from two groups (Figure 3-7c).  
MDSCs and Treg cells are well studied as immune suppressors that facilitate 
tumor progression as reviewed in Chapter 2. We therefore examined these two 
populations in tumors. As results shown in Figure 3-7d, there was no 
significant difference in percentage of tumor-infiltrating MDSCs (CD11b+Gr-




infiltrating CD4+CD25+Foxp3+ Treg cells was significantly reduced with 
deletion of STAT3 in endothelium (Figure 3-7e). This reduction seems to be 
independent of Treg generation, because loss of STAT3 in endothelium did 
not cause a significant change in percentage of Treg cells in spleens (Figure 3-
7f). Hence, these results indicate that Treg cell infiltration into tumors is 
selectively impaired by endothelial STAT3 deletion, presumably because loss 
of STAT3 in ECs disrupts the recruitment or extravasation of Treg cells to 
tumor microenvironment.  
Studies on cancer patients suggest that the suppression of tumor-specific CTL 
cytotoxicity may contribute to tumor progression (Wang et al., 2004). 
Therefore, the production of IFN-γ by tumor-infiltrating CD8+ T cells was 
assessed by intracellular staining and flow cytometry. Single cell suspensions 
from tumors were re-stimulated in cRPMI with PMA and ionomycin together 
with Golgiplug for 4 h before subject to intracellular cytokine staining. As a 
result, higher frequency of IFN-γ-producing CD8+ T cells was observed in 
tumors from Stat3-/- mice than those from Stat3+/+ mice (Figure 3-7g). 
Together, these data suggest an association of derepressed CD8+ T cell activity 
with decreased Treg infiltration, and suppressed tumor growth in endothelial 





Figure 3-7 Treg infiltration is selectively decreased in tumors with 
endothelial STAT3 deletion. 
LLC tumors engrafted in Stat3+/+ and Stat3-/- mice were removed about 16 
days after inoculation. Tumors were excised into small pieces and digested to 
obtain single cell suspensions, followed by staining and flow cytometry 
analysis.  
(a) Representative flow cytometry (left) and statistics (right) of tumor-
infiltrating leukocytes (n=5 per group). 
(b) Representative flow cytometry (left) and statistics (right) of the frequency 
of tumor-infiltrating CD11b+CD11c+ myeloid DCs (n=5 per group). 
(c) Statistics of CD4+ and CD8+ T cell frequencies in tumors from Stat3+/+ and 
Stat3-/- mice (n=5 per group). 
(d) Representative flow cytometry (left) and statistics (right) of the frequency 
of tumor-infiltrating CD11b+Gr-1+ MDSCs (n=5 per group). 
(e) Representative flow cytometry (left) and statistics (right) of the frequency 




(f) Representative flow cytometry (left) and statistics (right) of the frequency 
of splenic CD4+CD25+Foxp3+ Treg cells (n=5 per group). 
Data are representative of more than three independent experiments. 
(g) Statistics of the frequency of IFN-γ-producing CD8+ T cells in tumors 
from Stat3-/- and Stat3+/+ mice (n=4 per group). 
*p<0.05, ns not significant. 
 
3.2.8 Decreased Treg adhesion to STAT3-deficient ECs 
Adhesion of Treg cells to ECs is a crucial process for extravasation of Treg 
cells to reach tumor site. Given the defective infiltration of Treg cells in tumor 
with endothelial STAT3 deletion (Figure 3-7e), it is likely that the Treg 
adhesion to ECs is interfered by endothelial STAT3 deletion. To address this, 
adhesion of Treg cells to Stat3+/+ and Stat3-/- ECs was tested by a static Treg 
adhesion assay in vitro. In brief, Stat3+/+ and Stat3-/- primary ECs were 
cultured and pre-treated with TNF-α to upregulate the expression of cell 
adhesion molecules. Considering that majority of CD4+CD25+ T cells 
coexpress Foxp3 (Figure 3-7e and f), CD4 and CD25 markers were thus used 
to obtain viable Treg cells. CD4+CD25+ T cells were sorted from splenocytes, 
labeled with CellTrace CFSE dye, and then added to EC monolayers. 
Unattached Treg cells were gently washed out after 2 hours incubation and 
attached Treg cells were detected by green fluorescence. As expected, fewer 
Treg cells adhered to STAT3-deficient ECs in comparison to wild type ECs 
(Figure 3-8). This result may at least partially explain the defective infiltration 





Figure 3-8 Decreased Treg adhesion to STAT3-deficient ECs. 
(a and b) Representative images (a) and statistics (b) of Treg adhesion to 
Stat3+/+ and Stat3-/- ECs. CD4+CD25+ Treg cells were labeled with CellTrace 
CFSE dye and incubated with EC monolayers for 2 hours, followed by gentle 
washing to remove unattached Treg cell and subsequent observation of 
attached Treg cells.   
 
3.2.9 Potential targets of STAT3 in endothelial cells 
To discover potential target of STAT3 in ECs, we prepared samples for 
microarray analysis. IL-6 induced quick and persistent activation of STAT3 in 
primary ECs (Figure 3-9a). Therefore, we stimulate Stat3+/+ and Stat3-/- ECs 
with IL-6 to activate STAT3. IL-6 stimulation induced phosphorylation of 
STAT3 in Stat3+/+ ECs but not Stat3-/- ECs (Figure 3-9b). mRNA samples 
were collected and proceed for microarray analysis. 
From the microarray results, we were trying to discover genes that were 
upregulated in Stat3+/+ ECs upon IL-6 stimulation but failed to do so in Stat3-/- 
ECs. As shown in figure 3-9c, several genes displayed expression pattern as 
described above. The top two genes Sele and Serpina3n were verify through 




inflamed ECs. Treatment with LLC C.M. slightly increased expression of E-
selectin in SVECs (Figure 3-9e). It has been reported that in contrast to 
endothelium of normal tissues, tumor associated ECs express higher levels of 
E-selectin (Nummer et al., 2007). Blockade of E-selectin leads to dramatically 
reduced transmigration of Treg cells through tumor tissues-derived EC 
monolayers (Nummer et al., 2007). Together, Sele is a potential target for 
STAT3 in ECs to regulate Treg recruitment in tumor microenvironment.  
 
Legend of figure 3-9 Potential target of STAT3 in ECs 
(a) The expression of pSTAT3 (Y705), STAT3 and Actin in primary ECs 
treated with IL-6. 
(b)  Expression of pSTAT3 (Y705), STAT3 and Actin in Stat3+/+ and Stat3-/- 
ECs were assessed by western blot. 
(c) Microarray analysis of Stat3+/+ and Stat3-/- ECs treated with IL-6. 
(d) mRNA expression of Sele and Serpina3n were examined by RT-PCR. 
(e) The expression of SELE, pSTAT3 (Y705), STAT3 and Actin in SVEC 







Figure 3-9 Potential targets of STAT3 in ECs. 





This study aims at examining whether endothelial STAT3 plays a role in 
tumor development, especially in regulating tumor angiogenesis and tumor 
immune evasion. The observation that tumor cell-secreted soluble factors can 
quickly induce strong STAT3activation in primary endothelial cells (Figure 3-
1c), is consistent with previous studies showing phosphorylated STAT3 in 
tumor blood vessels (Couto et al., 2012; Kujawski et al., 2008; Schaefer et al., 
2002), which together implicate a potential role of endothelial STAT3 in 
regulating tumor development. 
For in vivo study of endothelial STAT3 function, we utilized a Cre/loxp mouse 
strain with STAT3 deletion specifically in endothelium, as previously 
described in details (Kano et al., 2003). In the subcutaneous tumor model with 
both Lewis LLC tumors and B16 melanoma tumors, we consistently showed 
that the tumor volumes in endothelial STAT3-deficient mice were markedly 
smaller than those of control mice, demonstrating that deletion of STAT3 in 
endothelium suppresses tumor growth (Figure 3-2). To further exclude effects 
from minor STAT3 deletion in bone marrow cells, we performed bone marrow 
transplantation to reconstitute bone marrow of Stat3-/- mice and control mice 
with STAT3-wild type bone marrow cells before subcutaneous tumor assay. 
With more than 90% efficiency of bone marrow reconstitution, endothelial 
STAT3-deficient mice still grew smaller tumors than control mice (Figure 3-3). 
These evidence supports that STAT3 expression and activation in ECs 




In pursuit of the mechanism underlying endothelial STAT3 function, we found 
that tumors excised from endothelial STAT3-deficient mice displayed reduced 
tumor vessel density, compared with tumors excised from control mice 
(Figure 3-4a and b). In vitro assay showed reduced tumor cell-derived factors–
induced migration of Stat3-/- ECs in comparison with Stat3+/+ ECs (Figure 3-
5f and g). Consistently with our previous report (Kano et al., 2003), deletion 
of STAT3 does not affect the tube formation of ECs under condition with 
sufficient growth factors (Figure 3-5b and c). However, STAT3 deficiency 
suppressed tube formation of ECs induced by tumor cell-secreted soluble 
factors (Figure 3-5d and e). Similar results have been reported that inhibition 
of STAT3 in ECs decreased tumor cell-derived factors-induced migration and 
tube formation (Kujawski et al., 2008; Lee et al., 2015). Our experiments were 
performed using a clean system with complete deletion of STAT3 in ECs 
(Figure 3-5a). In contrast, reported works by others used inhibitors or siRNA 
to inhibit activation of STAT3 in in vitro experiments (Kujawski et al., 2008; 
Lee et al., 2015).  
Higher level of hypoxia was observed in tumors from Stat3-/- mice (Figure 3-
4c and d). Hypoxia could induce angiogenesis through various pathways, 
including HIF-1 pathway (Harris, 2002). However, in our model, increased 
level of hypoxia in tumors from Stat3-/- mice failed to induce elevated tumor 
vessel density (Figure 3-4 a and b). We found that the expression level of HIF-
1α was reduced in STAT3-deficient ECs in comparison with control ECs 
(Figure 3-4e). Tang and colleagues demonstrated that loss of HIF-1α in ECs 




conditions, and mice with specific knock out of HIF-1α in endothelium have 
impaired tumor angiogenesis and reduced tumor size (Tang et al., 2004). 
Decreased expression of HIF-1α in STAT3-deleted ECs may help to partially 
explain why increased hypoxia in tumors from Stat3-/- mice cannot induce 
sufficient tumor angiogenesis to support tumor growth. 
In addition to its role in tumor angiogenesis, tumor-associated ECs also serve 
as regulators for tumor immune response (Boon et al., 2006; Lurquin et al., 
2005). Therefore, we examined the expression of chemokines, which are 
critical players in immune cell trafficking, in the tumors from Stat3-/- mice and 
control mice. From the chemokines and chemokine receptors screening, we 
found that selective chemokines and chemokine receptors were downregulated 
in tumors from Stat3-/- mice in comparison with tumors from Stat3+/+ mice 
(Figure 3-6). Among the downregulated chemokines, some chemokines are 
involved in Treg functioning and recruitment. For example, CCL1 has been 
reported to associate with suppressive function as well as elevated numbers of 
Treg cells in tumor microenvironment (Hoelzinger et al., 2010). Besides, 
CXCL16 and its receptor CCR5 are crucial for localization of Treg cells to 
tumor (Parsonage et al., 2012). Consistently, we observed reduced Treg cells 
infiltration in tumors from Stat3-/- mice (Figure 3-7e). In addition, in vitro 
assay showed decreased Treg adhesion to Stat3-/- ECs (Figure 3-8). From 
microarray analysis, we found that expression of E-selectin was reduced in 
STAT3-deficient ECs (Figure 3-9c and d). E-selectin has been reported to 




monolayers (Nummer et al., 2007). Hence, STAT3 might regulate Treg 
recruitment through expression of E-selectin on ECs. 
In summary, we demonstrated that endothelial-specific STAT3 promotes 
tumor growth, probably through multiple mechanisms, including enhancing 
tumor angiogenesis via pro-angiogenic pathways, and suppressing antitumor 
immunity through recruitment of immunosuppressive Treg cells. 
3.4 Future work 
In this project, we utilized subcutaneous tumor model to investigate the role of 
endothelial STAT3 in tumor development and revealed two processes-
promoting tumor angiogenesis and evading anti-tumor immunity, accountable 
for endothelial STAT3-mediated tumor growth. Yet, a few questions remain to 
be further addressed, and I thus proposed the following aspects of future work.  
If the finding that endothelial STAT3 facilitates tumor development is 
applicable to a broad spectrum of tumor types and tumor models? 
We used two types of tumors, LLC and B16, in this study and observed the 
similar results that endothelial STAT3 knockout suppresses tumor growth. We 
thus speculated that endothelial STAT3 generally facilities the development of 
multiple tumor types. To address this, more tumor types, such as EL-4, could 
be tested in subcutaneous tumor model of endothelial-STAT3 knockout mice.  
Subcutaneous tumor model is widely used in cancer studies, but it has certain 
limitation, for example its unsuitability in studying tumorigenesis. To better 




development, I planned to employ other tumor models in future study, in 
particular the spontaneous tumor models such as MMTV-PyVT mammary 
tumors and TRAMP prostate tumor. 
To what extent does HIF-1α and VEGFR2 account for STAT3-mediated 
tumor angiogenesis? 
We revealed severely defective tumor angiogenesis in the absence of STAT3 
and further found that both HIF-1α and VEGFR2, two key factors involved in 
tumor angiogenesis (Lee et al., 2015; Tang et al., 2004), were regulated by 
STAT3 in ECs. STAT3 transmits extracellular signals and acts as an important 
transcriptional factors with a broad spectrum of target genes. It is likely that 
there is a set of target genes contributing to STAT3-mediated tumor 
angiogenesis. Thus, the question is to what extent HIF-1α and VEGFR2 
account for such function of STAT3 in promoting angiogenesis. To address 
this, I proposed these experiments: retroviral expression of HIF-1α or/and 
VEGFR2 in STAT3-deficicent ECs in vitro followed by EC functional assays 
such as tube formation and transmigration, to see if HIF-1α or/and VEGFR2 
overexpression can rescue STAT3 defects; in vivo rescue assay in 
subcutaneous tumor model by virally transducing HIF-1α or/and VEGFR2 to 
ECs of endothelial-STAT3 knockout mouse; in vivo rescue assay by 
generating transgenic mouse strain with HIF-1α or/and VEGFR2 
overexpression specifically in ECs. Besides, I would also look into if other 




How does endothelial STAT3-regulated E-selectin mediate Treg 
infiltration into tumor mass? 
In this study, our results implicate that the decreased Treg infiltration into 
tumor mass inoculated in endothelial-STAT3 knockout mice may result from 
the disrupted interaction between Treg and ECs. Furthermore, we observed 
that the expression of E-selectin, which was reported to be involved in Treg 
and EC interaction (Nummer et al., 2007), was inducible by tumor cells and 
was likely regulated by STAT3. But how STAT3 regulates E-selectin 
expression in ECs in details needs to be further studied. We speculated that 
STAT3 activation directly transcribed gene expression of E-selectin. It is now 
known that Treg trans-endothelial migration involves multiple steps and 
various molecular players (Huehn and Hamann, 2005). Therefore, how EC-
expressed E-selectin mediates Treg transmigration in tumor microenvironment 
is worthy of exploration.  
What are the microenvironmental signals activating STAT3 and 
responsible for tumor angiogenesis and tumor evasion? 
We showed that certain tumor cell-derived soluble factor(s) can potently 
activate STAT3 in ECs, but haven’t characterized the nature of this/those 
factor(s). As described in Chapter 1.2, STAT3 activation through tyrosine 
phosphorylation is crucial for executing its function. There are plenty of 
extracellular signals, including cytokines, growth factors and hormones, able 
to induce STAT3 activation. In future study, I would try to characterize the 




STAT3-mediated angiogenesis and/or Treg transmigration. To this aim, mass 
spectrometric analysis of conditioned medium from tumor cell lines might be 
useful. Of note, we can’t exclude the possibility that STAT3 is activated by 
soluble factors secreted by non-tumor cells such as tumor-associated 
macrophages or by non-soluble factors such as cell-cell physical contact.  
Is STAT3 or STAT3-induced molecule a potential therapeutic target for 
controlling tumor development?  
Our results demonstrate a critical role of endothelial STAT3 in facilitating 
tumor growth and implicates a possibility of targeting STAT3 activation for 
controlling tumor progression. Several STAT3 chemical inhibitors are under 
clinical trials for treating malignant tumors, but they show limited efficacy or 
low tolerance (Yu et al., 2014). Findings from this study may shed new light 
on development of STAT3 antagonist targeting endothelial STAT3 expression 
or activation. In addition, STAT3-regulated molecules identified in this study 





CHAPTER 4 FUNCTION OF T-CELL-SPECIFIC STAT5 IN 
RHEUMATOID ARTHRITIS  
4.1 Introduction 
CD4+ T (Th) cells are crucial plays in both anti-pathogen defense and several 
types of autoimmune disease, including RA. Abundant T cells infiltrate in 
inflamed synovium of RA patients (Imboden, 2009). However, our knowledge 
on how T cells functionally mediate synovitis is limited. Th1 cells were 
previously considered as major effector in RA due to its dominant frequency 
in synovium (Berner et al., 2000). In the past decade, with tremendous efforts 
and focus made on it, Th17 is also demonstrated its critical role in various 
animal models of RA (Imboden, 2009). 
The functions of different Th subsets in pathogenesis of RA are largely 
dependent on their feature cytokines production (McInnes and Schett, 2007). 
For example, Th17 cells produce proinflammatory cytokines IL-17, IL-17F, 
IL-21and TNF-α, which can promote the mobilization and activation of innate 
immune cells such as macrophages and neutrophils, help B cell production of 
antibodies, and induce fibroblast proliferation (Azizi et al., 2013). However, it 
has been reported that the frequency of Th17 cells is low in both peripheral 
blood and synovium of RA patients (Yamada et al., 2008). Besides, mouse 
studies on function of Th1-derived IFN-γ revealed contrary results in murine 
model of RA (Manoury-Schwartz et al., 1997; Vermeire et al., 1997). 




GM-CSF nowadays is viewed as a proinflammatory cytokine more than a 
hematopoietic-cell growth factor (Hamilton, 2008; Hamilton, 2015). GM-CSF 
is an emerging therapeutic target for RA. RA patients display higher level of 
GM-CSF in synovial fluid (Bell et al., 1995). GM-CSF contributes to synovitis 
through multiple mechanisms, including mobilizing and activating dendritic 
cells, macrophages and neutrophils (Hamilton, 2015), and promoting 
generation of bone-resorbing osteoclasts (Lee et al., 2009). GM-CSF can be 
produced by multiple types of cells, including activated T and B cells, 
monocytes/macrophages, neutrophils, fibroblasts and endothelial cells. 
However, the detailed cellular sources of GM-CSF during the development of 
arthritis and its functional importance in RA remain largely unknown. 
In our previous report, we described a novel GM-CSF-producing Th subset, 
named Th-GM, which is essential for development of experimental 
autoimmune encephalomyelitis (EAE) (Sheng et al., 2014). The programming 
of Th-GM is mediated by IL-7-STAT5 axis. Mice with specific deletion of 
STAT5 in CD4+ T cells are less susceptible to EAE induction. Therefore, we 
furthered this study to investigate whether STAT5-regulated CD4+ T cells play 
a role in development of RA in mouse models. 
Researchers have developed many mouse models of RA to study the 
pathogenesis of disease (Bendele, 2001). In this project, we mainly utilized an 
acute T cell-driven arthritis model, named antigen-induced arthritis model. 
Antigens are administrated into joints and bind to cartilage, which later 
become target attacked by immune cells. Another chronic arthritis mouse 





4.2.1 Mice with T cell-specific deletion of STAT5 are highly resistant to 
development of experimental arthritis 
To study the role of STAT5-regulated CD4+ T cells in arthritis, we generated 
T cell-specific STAT5-deficient mice. To that end, Stat5f/f (Stat5+/+) mice were 
crossed with Cd4-Cre mice to generate Cd4-Cre; Stat5f/f (Stat5-/-) mice. Both 
Stat5a/b loci were deleted in this strain.  
Antigen-induced arthritis (AIA), an acute T-cell driven mouse model of RA, 
has been extensively used to explore role of mediators in RA pathogenesis 
(Brackertz et al., 1977; van de Loo et al., 1995; van Meurs et al., 1998). To 
induce AIA, Stat5-/- mice and Stat5+/+ mice were immunized by subcutaneous 
injection of methylated bovine serum albumin (mBSA) in complete Freund’s 
adjuvant (CFA) and subsequent intraperitoneal injection with pertussis toxin. 
mBSA in saline was intraarticularlly injected into the right hind knee joint at 
day 7 after immunization, while saline was intraarticularlly injected into the 
corresponding left hind knee joint as a control. Arthritis progression was 
assessed daily by measurement of joint swelling.  
Intraarticular injection of mBSA quickly induced joint swelling in wild-type 
mice (Figure 4-1a).  In contrast, Stat5-/- mice developed dramatically 
attenuated joint swelling (Figure 4-1a). Knee joints from AIA-induced mice 
were dissected at day 7 after disease induction (or day 14 after immunization) 
for histology analysis. As expected, milder inflammation with reduced 




destruction were revealed in Stat5-/- mice when compared with Stat5+/+ mice 
(Figure 4-1b and c). 
The susceptibility of Stat5-/- and Stat5+/+ mice to collagen-induced arthritis 
(CIA) induction, a chronic arthritis mouse model (Brand et al., 2007), was also 
examined. Stat5-/- mice and controls were subjected to immunization with 
chicken type II collagen/CFA emulsion and followed pertussis toxin injection. 
The score system is described as follows: 0, no evidence of disease; 1, mild 
ankle or wrist swelling, or apparent swelling of individual digits; 3, severe 
swelling of entire paw with anchylosis. The score for each mouse was 
calculated as summed sores for four limbs. Consistent with results from AIA 
model, Stat5-/- mice showed a lower susceptibility to CIA induction, as 
characterized by markedly reduced paw swelling and milder disease severity, 
when compared with controls (Figure 4-1d and e). Histological examination 
also revealed much few infiltrations of immune cells in joints dissected from 
Stat5-/- mice in comparison with wild-type mice (Figure 4-1f). All above 
results indicate that STAT5-regulated CD4+ T cells are crucial for 
development of experimental arthritis. 
Legend of Figure 4-1 Mice with T cell-specific deletion of STAT5 are 
resistant to AIA and CIA induction 
(a) Knee joint swelling of Stat5-/- and Stat5+/+ mice (n=6). Arthritis was 
induced by intraarticular injection of mBSA at right hind knee joint of each 
mouse at day 7 after immunization. Joint swelling was measured by the 
difference of diameters between two hind knee joints using a caliper. Data are 
representative of more than three independent experiments. 
(b) Representative H&E staining of joint sections from Stat5-/- and Stat5+/+ 
mice at day 7 after AIA induction. Bars, 500 μm (upper panels) or 100 μm 




(c) Representative Safranin-O/Fast Green staining of joint sections from Stat5-
/- and Stat5+/+ mice at day 7 after arthritis induction. Bars, 500 μm (upper 
panels) or 100 μm (lower panels).  
(d) Representative image of paw swelling of Stat5-/- and Stat5+/+ mice at day 
40 after CIA induction with chicken type II collagen/CFA emulsion. 
(e) Clinical scores of Stat5-/- and Stat5+/+ mice at day 40 after CIA induction 
(n=5). Data are representative of two independent experiments. 
(f) Representative H&E staining of paw sections from Stat5-/- and Stat5+/+ 
mice at day 40 after CIA induction. 
*p<0.05; **<0.005; ***<0.0005 
 
Figure 4-1 Mice with T cell-specific deletion of STAT5 are resistant to 




4.2.2 STAT5-deficient CD4+ T cells have intrinsic defect in arthritogenicity 
Given the observation that mice with T cell-specific deletion of STAT5 are 
resistant to development of experimental arthritis, we first examined whether 
loss of STAT5 causes defect in development of CD4+ T cells. The spleens and 
inguinal lymph nodes (LNs) were harvested from Stat5-/- and Stat5+/+ mice 
and analyzed by flow cytometry. Comparable percentage of CD4+ T cells 
between Stat5-/- and Stat5+/+ mice was observed (Figure 4-2a and b), which is 
consistent with a previous report (Burchill et al., 2007). To assess the effect of 
STAT5 deficiency on infiltration of CD4+ T cells in synovial tissues, synovial 
tissues from AIA-induced mice were dissected and digested to analyze by 
flow cytometry. As results shown in Figure 4-2c, similar frequencies of 
infiltrating CD4+ T cells among leukocytes were observed between Stat5-/- and 
Stat5+/+ mice, suggesting that loss of STAT5 in CD4+ T cells dose not impair 
their infiltration in synovial tissues. 
With above results, we hypothesized that loss of STAT5 may cause defective 
arthritogenic potential of CD4+ T cells. To test this hypothesis, peripheral 
lymphoid tissues were harvested from AIA-induced Stat5-/- and Stat5+/+ mice, 
cultured with mBSA and IL-7 for 3 days, and purified to obtain antigen-
reactive CD4+ T cells. Stat5-/- and Stat5+/+ antigen-reactive CD4+ T cells were 
then transferred into wild-type naïve mice, separately, and followed by intra-
articular injection of mBSA on the second day. Adoptive transfer of Stat5+/+ 
antigen-reactive CD4+ T cells induced extensive infiltration of immune cells 
in synovial tissues (Figure 4-2d). By contrast, mice receiving STAT5-deficient 




synovial tissues at day 7 after AIA induction (Figure 4-2d). Taken together, 
above results demonstrate that STAT5-deficient CD4+ T cells are defective in 
arthritogenicity. 
 
Figure 4-2 Loss of STAT5 causes defective arthritogenic potential of CD4+ 
T cells   
(a and b) Percentages of CD4+ T cells in spleens (a) and inguinal LNs (b) of 
Stat5-/- and Stat5+/+ mice at day 7 after AIA induction. 
(c) Frequencies of infiltrated CD4+ T cells among leukocytes in synovial 
tissues from Stat5-/- and Stat5+/+ mice at day 7 after AIA induction (n=5). 
Synovial tissues were dissected from AIA-induced mice and digested to 
analyze by flow cytometry. Data are representative of two independent 
experiments.  
(d) Representative H&E staining of joint sections from mice receiving in vitro 
expanded Stat5-/- and Stat5+/+ antigen-reactive CD4+ T cells. 




4.2.3 Selectively impaired production of GM-CSF by STAT5-deficient CD4+ 
T cells  
CD4+ T cell-derived proinflammatory cytokines are crucial mediators for 
early pathogenesis of RA (Arthritis Rheum 62, 383, J Autoimmun 39, 222, 
Nat Rev Immunol 7, 429). Therefore, we first measured levels of 
proinflammatory cytokines in serum of AIA-induced mice by ELISA. The 
level of GM-CSF was selectively reduced in Stat5-/- mice compared with 
Stat5+/+ mice, whereas the levels of IFN-γ and TNF-α were increased (Figure 
4-3a).  
Next, we examined the major producer of GM-CSF. Splenocytes were isolated 
from wild type AIA-induced mice and separated to two groups, CD4+ T cells 
and CD4+ T cells-depleted splenocytes, by CD4 Microbeads from Miltenyi. 
Under conditions of non-stimulation and various stimuli, production of GM-
CSF by splenocytes depleted of CD4+ T cells was limited compared to that of 
total splenocytes (Figure 4-3b). In contrast, CD4+ T cell populations produced 
markedly increased GM-CSF (Figure 4-3b), indicating that CD4+ T cell are 
the major producer of GM-CSF. 
The frequency of GM-CSF-positive cells among CD4+ T cells were also 
assessed in AIA-induced Stat5-/- and Stat5+/+ mice. Splenocytes were isolated 
and restimulated with PMA/Inomycin plus Golgiplug ex vivo. Intracellular 
cytokine staining analyzed by flow cytometry showed significantly reduced 
GM-CSF-single-producing cells among CD4+CD44hi effector T cells in Stat5-/- 




Th17 cells and IFN-γ-single-producing Th1 cells yielded no significant 
difference between two groups. In summary, above results demonstrate that 
loss of STAT5 in CD4+ T cells specifically suppress GM-CSF production in 
experimental arthritis. 
 
Legend of figure 4-3 Impaired GM-CSF production by STAT5-deficient 
CD4+ T cells in AIA 
(a) Measurement of proinflammatory cytokines (GM-CSF, IFN-γ, and TNF-α) 
in serum of AIA-induced mice by ELISA (n=8). Serum were collected from 
Stat5-/- and Stat5+/+ mice at day 7 after AIA-induction. Protein levers were 
measured by ELISA. 
(b) Measurement of GM-CSF produced by indicated cell populations by 
ELISA. Splenocytes were isolated from AIA-induced mice and separated to 
CD4+ T cells and splenocytes depleted of CD4+ T cells (CD4-negative 
splenocytes). Cells were untreated or treated with indicated stimuli. 
Supernatant were collected for ELISA assay. 
(c) Representative flow cytometric analysis (left) and statistics (right) of 
intracellular staining of GM-CSF, IL-17, and IFN-γ gated by CD4+CD44hi 
effector T cells from Stat5-/- and Stat5+/+ spleens at day 7 after AIA-induction 
(n=5). Splenocytes were isolated, restimulated with PMA/Inomycin plus 
Golgiplug for 4 h, and analyzed by intracellular staining and flow cytometry. 
Data represent two independent experiments. 






Figure 4-3 Impaired GM-CSF production by STAT5-deficient CD4+ T 
cells in AIA  




4.2.4 Loss of STAT5 causes selectively reduced GM-CSF-producing CD4+ T 
cells in synovial tissues 
Synovial tissues from RA patients display abundant T cells, among which Th1 
and Th17 cells are believed as critical effectors (McInnes and Schett, 2011). 
Our result showed comparable percentage of CD4+ T cells in synovial tissues 
from AIA-induced Stat5-/- and Stat5+/+ mice (Figure 4-2c). To assess the 
properties of arthritogenic Th subsets and their regulation by STAT5 in 
synovitis, synovial tissues were dissected from AIA-induced mice and 
analyzed by flow cytometry. As shown by figure 4-4a, selectively reduced 
percentage of GM-CSF-producing Th cells was observed in synovial tissues 
from Stat5-/- mice. Of note, certain Th populations (GM-CSF+IL-17+ and GM-
CSF+IFN-γ+ cells) produce more than one type of cytokines (Figure 4-4a). The 
percentages of Th1 (IFN-γ-single-positive) and Th17 (IL-17-single-positive) 
were similar between two groups (Figure 4-4a). We further demonstrated that 
CD4+ T cells were prominent producer of GM-CSF in synovial tissues of AIA 
mice (Figure 4-4b). Together, these results indicate that deletion of STAT5 in 
T cells specifically reduced the production of GM-CSF in synovial tissues 





Figure 4-4 Loss of STAT5 leads to selectively reduced production of GM-
CSF in synovial tissues from AIA-induced mice.  
(a) Representative flow cytometric analysis (left) and statistics of intracellular 
staining of GM-CSF, IL-17, and IFN-γ in CD4+ T cells from synovial tissues 
(n=3). Synovial tissues were dissected at day 7 after AIA induction, digested, 
and restimulated with PMA/Inomycin plus Golgiplug for 4 h, and analyzed by 
intracellular staining and flow cytometry. 
(b) Representative flow cytometry plot of GM-CSF and CD4 gated by CD45+ 
cells from synovial tissues. 






4.2.5 Insufficient production of GM-CSF by STAT5-deficient CD4+ T cells 
attenuates synovial inflammation 
Given reduced GM-CSF-producing T cells in synovial tissues from Stat5-/- 
mice, we expected decreased level of GM-CSF in synovial compartments. 
Synovial tissues from AIA-induced mice were dissected and lysed to extract 
proteins for ELISA. As expected, lower level of GM-CSF was detected in 
synovial tissues from Stat5-/- mice compared with Stat5+/+ mice (Figure 4-4a). 
Moreover, a group of proinflammatory cytokines, including TNF-α, IL-6, and 
IL-1β, was reduced in synovial tissues from Stat5-/- mice (Figure 4-4a), 
suggesting attenuated synovitis due to deficient of STAT5 in CD4+ T cells.  
Therefore, we hypothesized that STAT5-regulated production of GM-CSF in 
Th cells is crucial for evoking synovial inflammation in development of 
experimental arthritis. To test it, GM-CSF was administrated together with 
mBSA via intraarticular injection to hind knee joints. In Stat5+/+ mice, 
administration of GM-CSF exacerbated arthritis, as characterized by enhanced 
immune cell infiltration and cartilage destruction (Figure 4-5b and c). Without 
additional injection of GM-CSF, mBSA injection failed to induce synovial 
inflammation in Stat5-/- mice (Figure 4-5b). However, GM-CSF administration 
restored synovial inflammation and cartilage depletion in STAT5-deficient 
mice (Figure 4-5b and c). Together, above results indicate that attenuated 
synovial inflammation in Stat5-/- mice was due to impaired production of GM-





Figure 4-5 Insufficient production of GM-CSF by STAT5-deficient Th 
cells in synovial tissues results in attenuated inflammation.  
(a) Measurement of levels of proinflammatory cytokines in synovial tissues by 
ELISA (n=5). Synovial tissues were dissected at day 7 after AIA induction 
and lysed to extract proteins for ELISA. 
(b and c) Representative histological analysis of joint sections stained by H&E 
(b) and Safranin-O/Fast Green (c) at day 7 after AIA induction. GM-CSF was 
administrated together with mBSA by intraarticullar injection to left hind knee 
joints, whereas mBSA alone was injected to right hind knee joints. Bars, as 
indicated. 





4.2.6 Disrupted myeloid cell accumulation in synovial tissues of Stat5-/- mice 
in development of AIA 
Having demonstrated that synovial inflammation was associated with GM-
CSF produced by Th cells in synovial tissues, we further investigate the 
underlying mechanisms. GM-CSF regulates the activation and proliferation of 
several cell types, including macrophages and neutrophils (Hamilton, 2008), 
which are viewed as effector cells in RA (Cornish et al., 2009). Therefore, we 
examined the frequency of infiltrated myeloid cells in synovium of AIA-
induced mice. Strikingly, CD11b+ myeloid cells represented more than 70% of 
synovial infiltrating leukocytes at day 7 after AIA induction (Figure 4-6a and 
b). This percentage was markedly decreased in Stat5-/- mice (Figure 4-6a and 
b).   
We then assessed the frequency of synovium-infiltrating myeloid cells over a 
7-day time course. As shown in Figure 4-6b, the percentage of CD11b+ 
myeloid cells was gradually increased after AIA induction in wild-type mice, 
suggesting a persistent accumulation of myeloid cells in synovial tissues. 
However, this accumulation was disrupted by STAT5 deletion in CD4+ T cells 





Figure 4-6 STAT5 deletion in CD4+ T cells suppresses myeloid cell 
accumulation in synovium.  
(a) Synovial tissues were dissected from AIA-induced mice at day 7 after 
arthritis induction and CD11b+ myeloid cells were analyzed by flow cytometry. 
(b) Quantification of synovium-infiltrating myeloid cells among CD45+ 
leukocytes (n=5). 
(c) Percentage of CD11b+ myeloid cells gated by CD45+ leukocytes in 







4.2.7 STAT5-regulated CD4+ T cells-derived GM-CSF mediates neutrophil 
accumulation in synovial tissues 
CD11b+ cells can be further divided into several cell types, including 
monocytes, macrophages, eosinophils, and neutrophils. These populations 
could be distinguished by expression levels of marker Ly6C and Ly6G (Rose 
et al., 2012). We then collected synovial tissues over a 7-day time course after 
AIA induction and analyzed different populations among CD11b+ myeloid 
cells. We observed a greatly and gradually accumulated Ly6CloLy6Ghi 
population in synovium of wild-type AIA-induced mice (Figure 4-7a). This 
population was the dominant cell population (>80%) among synovium-
infiltrating myeloid cells at day 7 after AIA induction (Figure 4-7a). In 
contrast, Ly6CloLy6Ghi population was dramatically reduced and also failed to 
continuously accumulate in synovium of Stat5-/- mice after AIA induction 
(Figure 4-7a).  
Ly6CloLy6Ghi population has been recognized as neutrophils (Rose et al., 
2012). To confirm that the accumulated Ly6CloLy6Ghi population in synovial 
tissues was neutrophils, we sorted out Ly6CloLy6Ghi cells and Ly6ChiLy6G- 
cells from digestion of synovial tissues from AIA-induced mice. Cells 
suspensions were cytospun to slides and stained with May-Grunwald and 
Giemsa solutions. As expected, Ly6CloLy6Ghi cells exhibited typical 
neutrophil morphology with ring-shaped and multi-lobed nucleus (Figure 4-
7b). In contrast, synovium infiltrating Ly6ChiLy6G- cells displayed 
mononuclear morphology (Figure 4-7b), indicating that they were probably 




were accumulated in synovial tissues during development of AIA in wild type 
mice, and failed to do so in Stat5-/- mice. 
Intraarticular administration with GM-CSF rescued the suppressed immune 
cell infiltration and cartilage erosion in synovial tissues of STAT5-deficient 
mice, as described in section 4.2.5. We also found that GM-CSF 
administration restored neutrophil accumulation in synovium of Stat5-/- mice 
(Figure 4-7c).  As discussed in section 4.2.4, GM-CSF was mainly produced 
by CD4+ T cells in synovial tissues. In conclusion, STAT5-regulated Th cells 
produced GM-CSF is crucial for accumulation of neutrophils in synovial 





Figure 4-7 STAT5 regulated production of GM-CSF in Th cells mediates 
accumulation of neutrophils in synovial tissues in AIA.   
(a) Ly6C and Ly6G markers of synovium infiltrating myeloid (CD45+CD11b+) 
cells were analyzed by flow cytometry. Synovial tissues were collected from 
AIA-induced mice at indicated days and were digested to obtain single cell 
suspensions for flow cytometric analysis. 
(b) Giemsa staining of synovium infiltrating Ly6CloLy6Ghi cells and 
Ly6ChiLy6G- cells. Ly6CloLy6Ghi cells exhibited neutrophil morphology, 
whereas Ly6ChiLy6G- cells exhibited mononuclear morphology.  
(c) Administration of GM-CSF boosted neutrophil accumulation in AIA. GM-
CSF was administrated together with mBSA by intraarticullar injection to left 




4.2.8 GM-CSF promotes transendothelial migration and survival of 
neutrophils in vitro 
Neutrophils need to extravasate through the vascular endothelium to arrive at 
the inflammatory sites (Amulic et al., 2012). This process comprises 
complicated neutrophil-endothelial cell interaction, including neutrophil 
capture, rolling, tight adhesion, and exit from blood vessels, which can be 
stimulated by various cytokines and chemoattractants (Amulic et al., 2012). 
Thereby, we performed in vitro neutrophil transendothelial assay, in which 
GM-CSF was added as chemoattractant. Neutrophils were isolated from 
mouse spleens, stained with CellTrace CFSE dye, and added into the upper 
inserts that pre-coated with a SVEC monolayer. GM-CSF was added to the 
medium in the lower wells of experimental group. Neutrophils were allowed 
to migrate for 3 h. As shown by figure 4-8a and b, GM-CSF enhanced 
transendothelial migration of neutrophils, suggesting that GM-CSF produced 
by STAT5-regulated Th cells may help to recruit neutrophils to synovium 
through enhanced neutrophil extravasation.  
Neutrophils have a relatively short life span (12~18 h) in peripheral blood due 
to tightly regulated apoptosis (Wright et al., 2010). However, the apoptosis of 
neutrophils is delayed in joints of RA patients (Wright et al., 2010). Thus, we 
examined the effect of GM-CSF on apoptosis of neutrophils. We isolated and 
cultured neutrophils with or without GM-CSF for 24 h. Apoptotic neutrophils 
were detected by co-staining with annexin V and propodium iodide (PI). As 
demonstrated in figure 4-8c, GM-CSF promoted survival and delayed 




neutrophils in synovial tissues, probably through increased extravasation from 
blood vessels as well as enhanced survival of neutrophils. 
 
Figure 4-8 GM-CSF promotes transendothelial migration and survival of 
neutrophils in vitro 
(a) Percentage of transendothelial migrated neutrophils among total applied 
cells with or without GM-CSF as chemoattractant 3 h post start. Neutrophils 
that migrated to the lower wells were counted by a hemacytometer.  
(b) Neutrophils that migrated to the lower wells were centrifuged to the 
bottom and observed under fluorescence microscopy.  
(c) Neutrophils were isolated and cultured with or without GM-CSF for 24 h. 







4.2.9 GM-CSF promotes cytokine production by myeloid cells and synovial 
fibroblasts 
Cytokines regulate a broad spectrum of immune and inflammatory processes 
in RA (McInnes and Schett, 2007). In section 4.2.5, I described reduced levels 
of proinflammatory cytokine in synovial tissues from Stat5-/- mice compared 
with controls. Deletion of STAT5 specifically impaired GM-CSF production 
in synovium infiltrating Th cells (Figure 4-4a). We further studied whether 
GM-CSF could enhance cytokine productions by effector cells in synovial 
tissues. Myeloid cells and synovial fibroblasts are important players as well as 
cytokine producers in RA (McInnes and Schett, 2007). Therefore, we isolated 
and cultured bone marrow-derived macrophages (BMDMs), bone marrow-
derived dendritic cells (BMDCs), and synovial fibroblasts.  
To obtain BMDMs, bone marrow cells were cultured in presence of M-CSF 
for 7 days. To obtain BMDCs, culture medium was supplemented with GM-
CSF. Culture medium was changed two times. Cells were left to grow for 4 
more days and were passaged on day 8. Suspension cells collected on day 10 
were mature BMDCs. Synovial fibroblasts were isolated from AIA-induced 
mice. Supernatant of synovial tissue digestion was centrifuged and 
reconstituted in 10% FBS/DMEM. Medium was changed every three days. 
Small pieces of tissues were removed from the culture dish after groups of 
cells were observed. Cells were passaged for more than 5 times to obtain 
synovial fibroblasts. Purity of BMDMs, BMDCs, and synovial fibroblasts 




GM-CSF treatment quickly stimulated upregulation of IL-6 and IL-1β in 
BMDMs and BMDCs (Figure 4-9a and b). ELISA result also showed that 
GM-CSF significantly enhanced secretion of IL-6 and IL-1β from BMDMs in 
a dosage-dependent manner (Figure 4-9c). The mRNA expression level of IL-
1β in synovial fibroblasts was increased upon GM-CSF stimulation for 1 h 
(Figure 4-9d). Taken together, in addition to its role in neutrophil 
accumulation, GM-CSF may also enhance synovial inflammation through 
eliciting cytokine production by myeloid cells and fibroblasts. 
 
Figure 4-9 GM-CSF induces cytokine production in myeloid cells and 
synovial fibroblasts. 
(a and b) The mRNA expression of IL-6 and IL-1β in BMDMs (a) and 
BMDCs (b) upon stimulation of GM-CSF for 1 h. 
(c) Level of IL-6 in supernatant of BMDMs with GM-CSF stimulation at 
indicated dosages was assessed by ELISA.  
(d) Synovial fibroblasts were treated with GM-CSF for 1 h. mRNA level of 





The aberrant immune responses against self cells or tissues results in 
autoimmunity and inflammatory disorders. CD4+ helper T cells play a central 
role in orchestrating adaptive and innate immune response, and thus are 
crucial effectors in multiple types of autoimmune diseases, such as multiple 
sclerosis (MS) and RA. Multiple lines of evidence, including immunogenetics 
of RA (Okada et al., 2014), T-cell accumulation in synovium and findings 
from animal models (Komatsu and Takayanagi, 2012), support a central role 
of T cells in RA. However, the pathogenic mechanism of T cells remains 
insufficiently understood.  
Recent progression including published finding from our laboratory has 
supported a prominent and nonredundant role of Th cell-derived GM-CSF in 
MS and EAE (Sheng et al., 2014). Moreover, GM-CSF-single-producing Th 
cells programmed by IL-2/7-STAT5 signaling was proposed as a distinct 
subset of Th cells in both mouse and human (Sheng et al., 2014). In this study, 
we further showed that STAT5-regulated GM-CSF-producing Th cells are 
crucial for mediating synovial inflammation in the development of 
experimental arthritis. Mechanistically, Th cell-secreted GM-CSF leaded to 
accumulation of neutrophils in synovial tissues as well as the induction of 
proinflammatory cytokines from monocytes/macrophage, dendritic cells (DCs) 
and synovial fibroblasts, which together caused synovitis. 
It was known that GM-CSF knockout mice were resistant to CIA some time 




CSF in vivo (Hamilton, 2008), the predominant producer of the required GM-
CSF for arthritis development remains unclear then. In addition, this strain of 
GM-CSF knockout mice was generated by conventional gene targeting rather 
than conditional gene targeting (Stanley et al., 1994), which restrains the 
application of tissue-specific Cre technology to study the cellular types-
restricted functions of GM-CSF. We have recently identified STAT5 as a 
crucial transcriptional factor for the secretion of GM-CSF in response to 
cytokine stimulation and for the differentiation of GM-CSF-producing Th 
cells (Sheng et al., 2014). By introducing Cd4-Cre to Stat5-floxed mice, we 
were able to specifically delete STAT5 in T cells in vivo and thus use these 
mice for arthritis study. As a result, in parallel to GM-CSF knockout, T cell-
specific deletion of STAT5 protected mice from both AIA and CIA, 
accompanied with minimal or mild synovitis (Figure 4-1). We further 
demonstrated that this resistance to arthritis development was caused by 
defective arthritogenic potential of CD4+ T cells with loss of STAT5 (Figure 
4-2). In consistence with the critical role of STAT5 in GM-CSF expression, 
STAT5-deficient effector T cells were impaired in GM-CSF secretion while 
competent in IL-17 and IFN-γ secretion (Figure 4-4a), which suggests the 
requirement of STAT5-regulated GM-CSF-producing Th cells for arthritis 
development. This notion was further evidenced by the observation that 
exogenous GM-CSF administration to mice with T cell-specific STAT5 
deletion can restore arthritis development (Figure 4-5b and c). We cannot fully 
exclude other STAT5-regulated events in T cells that possibly contribute to 
synovitis and arthritis development, such as IL-3 secretion, but GM-CSF 




proposed that GM-CSF secretion by arthritogenic Th cells has a crucial and 
nonredundant role in mediating synovitis and arthritis development.  
An important question is how GM-CSF mediates synovitis that is essential for 
arthritis development. GM-CSF nowadays is more considered as a 
proinflammatory cytokine than a hematopoietic-cell growth factor. The GM-
CSF receptor is mainly expressed in myeloid-derived cells, though also in 
some non-hematopoietic cells such as endothelial cells (Nagy et al., 2007). 
Given the involvement of innate immune cells in RA pathogenesis (McInnes 
and Schett, 2011), it is very likely that GM-CSF act on innate immune cells, 
including monocytes/macrophages, DCs and neutrophils, to foster synovitis.  
Indeed, STAT5-induced GM-CSF accumulated CD11b+ cell in synovial 
tissues in AIA model (Figure 4-6). We demonstrated that a dominant 
population among CD11b+ cells were neutrophils, which massively infiltrated 
synovial tissues of wild-type AIA mice but not in STAT5-deficeint mice 
(Figure 4-7). This observation in mouse is consistent with the characterized 
neutrophil infiltration in massive numbers in synovial fluid and tissues of RA 
patients (Wright et al., 2014). Neutrophils exhibit great cytotoxic potential and 
contribute to RA pathogenesis in multiple ways, and neutrophil influx to joints 
are closely related with disease severity (Wright et al., 2014). In vitro assay 
showed that GM-CSF executed function at least through delaying neutrophil 
apoptosis and mediating neutrophil transendothelial migration (Figure 4-8). 
Therefore, neutrophils are one of major targets of Th cell-derived GM-CSF, 




Monocytes/macrophages are critical effectors of synovitis (McInnes and 
Schett, 2011) and DCs are involved in disease maintenance and progression 
(Khan et al., 2009). Although the synovial infiltration of 
monocytes/macrophage or DCs was not obviously altered in number by 
impaired GM-CSF production in AIA, we found a significant reduction of 
several proinflammatory cytokines such as IL-6 and IL-1β in synovial tissues 
of STAT5-conditional knockout AIA mice (Figure 4-5a). Both IL-6 and IL-1β 
were typically produced by myeloid cells, and results from in vitro assays 
suggest a stimulatory effect of GM-CSF on the expression of IL-6 and IL-1β 
(Figure 4-9).The mutual interaction between Th cells and myeloid cells via 
cytokine communication in RA is worthy of further investigation. 
GM-CSF is emerging cytokine target in RA (Burmester et al., 2014; Cornish 
et al., 2009). Antibodies targeting GM-CSF or GM-CSF-Rα are clinically tried 
to treat RA and show promising efficacy (Behrens et al., 2015; Burmester et 
al., 2013). However, the cellular sources of pathogenic GM-CSF and the 
regulatory mechanism of GM-CSF expression in RA remain elusive. It was 
recently reported that synovial CD4+ T cells could be a major source of GM-
CSF in inflamed joints of RA patients, supporting our findings using mouse 
arthritis models (Reynolds et al., 2015). Thus, our study implies the promise of 




4.4 Future work 
In this project, we revealed the novel role of T-cell-specific STAT5 in 
development of experimental arthritis. STAT5 controlled expression of GM-
CSF in T cells, which regulated arthritis development through promoting 
neutrophils accumulation and enhancing production of proinflammatory 
cytokines in synovial tissues. However, a few questions remain to be 
elucidated. 
What are the upstream signals that regulate STAT5 activation and induce 
GM-CSF production in T cells? 
In our previous report, we demonstrated that IL-7 activates STAT5 in CD4+ T 
cells and promotes GM-CSF production (Sheng et al., 2014). Blockade of IL-7 
signaling leads to reduced GM-CSF production by CNS-infiltrating Th cells, 
and suppresses EAE development in mice (Sheng et al., 2014). Elevated level 
of IL-7 has been reported in joints of RA patients (Chen et al., 2013). Is IL-7 
the major stimulator of STAT5 and inducer of GM-CSF in the development of 
AIA and CIA? To address this, I proposed to first examine the dynamic 
expression of IL-7 in synovial tissues over the process of arthritis development 
by measuring mRNA (RT-PCR) and protein level (ELISA). Next, the 
histological and immunohistological analysis would be performed to 
characterize the localization and cellular sources of IL-7 in synovial 
compartments. Then, the expression of IL-7 receptor on autoreactive Th cells 
in synovial compartment would also be studied to examine the responsiveness 




To test the in vivo function of IL-7 in arthritis development and IL-7 signaling 
in GM-CSF-producing Th generation and function, I planned to administrate 
IL-7 or IL-7Rα blockade antibody to AIA mice, and examined the 
corresponding effects on disease development and GM-CSF production by Th 
cells. 
Are GM-CSF-producing Th cells associated with human RA? 
In this study, we demonstrated that GM-CSF-producing Th cells are crucial 
for experimental arthritis. Thus, I wonder if GM-CSF-producing Th cells were 
in association with human RA. To address this, I first planned to quantify the 
frequency of GM-CSF-producing Th cells in the peripheral blood of RA and 
healthy control (HC), with the assumption that there might be an increased 
frequency in RA compared with HC. I would also examine the GM-CSF 
concentration in plasma of RA patients and HC, with an expectation that 
higher concentration of GM-CSF in RA plasma. A question that if there is a 
correlation between GM-CSF-producing Th cells and plasma GM-CSF will 
also be looked into. 
To further reveal a possible association of GM-CSF-producing Th cells with 
RA, I would examine the presence and abundance of GM-CSF-producing Th 
cells in the inflamed synovial compartments of RA patients. A histological 
analysis of synovial tissues might also be analyzed. In addition, the 
concentration of GM-CSF in synovial fluid of RA patients and osteoarthritis 




investigate if the frequency/abundance of GM-CSF-producing Th cells 
correlate with the disease severity of RA.  
How do GM-CSF-producing Th cells infiltrate into synovial compartment?  
We showed that in STAT5-deficient mice, the frequency of GM-CSF-
producing Th cells was selectively reduced in inflamed synovial tissues. 
Therefore, a question that how do these cells migrate to synovial tissues might 
be worth investigation. Studies on other Th subsets give insight to this 
question. In a mouse model, inflamed synovial tissues express CCL20 to 
recruit CCR6-expressing Th17 cells (Hirota et al., 2007). Chemokines CCL2, 
CCL5, and CXCL12 crucial for attracting Th1 cells to rheumatoid synovial 
tissues (Shadidi et al., 2003). Therefore, I planned to examine expression of 
chemokines and chemokine receptors to address the question. Firstly, I would 
examine the mRNA expression (RT-PCR) of different chemokines in synovial 
tissues from AIA mice. Secondly, I would also analyze expression of 
chemokine receptors on synovium-infiltrating GM-CSF-producing Th cells by 
flow cytometry. Thirdly, I would examine whether blockade of potential 
chemokines or chemokine receptors could inhibit migration of GM-CSF-
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